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INTRODUCTION 
Hypertension during pregnancy is one of the well known complications 
dating from ancient times. It remains as one of the leading causes of maternal 
mortality and morbidity through its myriad complications.   
This common medical disorder of pregnancy represents about 7 to 15% 
of all pregnancies and accounts for nearly 25% of admissions in antenatal 
wards1. And hypertensive disorders account for 16% of maternal mortality 
worldwide, according to the WHO analysis of causes of maternal death2. Of the 
studies conducted in India, the prevalence of gestational hypertension was 
found to be about 7.8%3.   
However this figure is increasing as women postpone their first 
pregnancy and also because of increasing metabolic complications like obesity. 
But, the incidence of complications is decreasing in developed nations due to 
better antenatal services. Apart from the various deleterious antenatal 
complications, pregnancy induced hypertension also poses a life long risk for 
the woman by transforming itself into chronic hypertension and also by 
increasing the woman’s cardiovascular risk. Hypertension during pregnancy 
along with proteinuria also adversely affects the neonate’s health by being the 
leading cause of stillbirth, fetal growth restriction, low birthweight and 
admissions to neonatal intensive care units. For a disorder with such vast 
implications, it is a relatively easier condition to diagnose provided a woman is 
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given proper antenatal care and blood pressure monitoring. Hence, the 
importance of studying this disorder in great lengths arises. 
 This study was undertaken to evaluate the demographic profile and 
the present status of maternal and perinatal outcomes throughout the spectrum 
of hypertensive disorders of pregnancy including mild, severe preeclampsia, 
eclampsia and chronic hypertension at Chengalpattu Medical College Hospital, 
Chengalpattu in a period of 1year from October 2016 to September 2017. 
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REVIEW OF LITERATURE 
National High Blood Pressure Education Program Working Group 
(NHBPEP 2000) working along with American College of Obstetricians and 
Gynecologists (ACOG) has set the definition and classification for the 
‘hypertension during pregnancy’4. Accordingly, Hypertension in Pregnancy is 
defined as Systolic pressure more than 140 mmHg and/or Diastolic pressure 
more than 90 mmHg (Korotkoff V/Disappearance of sound). Two pressure 
readings taken at 4 to 6 hours apart are needed for confirmation.  
 The Spectrum of hypertensive disorders of pregnancy consists of the 
following five:  
• Gestational Hypertension 
• Preeclampsia 
• Eclampsia 
• Preeclampsia superimposed on Chronic hypertension 
• Chronic Hypertension 
 
Gestational Hypertension is the elevated blood pressure of more than 140/90 
mmHg with its first onset noted after 20 weeks of gestation. It may also be 
noted during labour or in the first 24 hours postpartum but there must be no 
proteinuria. The elevated blood pressure has to resolve to normal within 12 
weeks postpartum and hence the final diagnosis is made only postpartum.   
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Blood pressure is measured in upright or left lateral recumbent position. 
Appropriate bladder cuff encircling two-thirds of the arm has to be used at the 
level of heart. Mercury sphygmomanometers remain the gold standard for 
measurement. Earlier, a raise of 30 mmHg systolic or 15 mmHg diastolic above 
the baseline used to be a diagnostic criterion but is now abandoned5. 
It is termed as Preeclampsia when gestational hypertension is associated with 
proteinuria. Proteinuria is defined as excretion in the urine of more than 300 mg 
protein in 24 hours or 1+ by reagent strips (30mg/dl) in atleast 2 random urine 
samples 4 to 6 hours apart. A spot urine protein:creatinine ratio is also currently 
preferred and has to be a value >0.3  
Even in the presence of proteinuria, it is classified as Severe Preeclampsia 
when the pressure exceeds 160/110 mmHg and the proteinuria more than 2g per 
24 hours or 2+ by reagent strips. The presence of imminent symptoms like 
persistent headache, persistent epigastric pain and oliguria also qualify for 
classification under severe preeclampsia. These persistent symptoms, earlier 
referred to as ‘imminent eclampsia’ are nothing but the manifestations of 
multiorgan involvement of the disease. In addition, microangipathic hemolysis, 
elevated liver enzymes, elevated serum creatinine (>1.2 mg/dl), reduced 
platelets (<1,00,000/µl) and pulmonary edema characterize severe preeclampsia.  
When a patient with preeclampsia presents with convulsions that cannot be 
attributed to other causes, then it is Eclampsia. 
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Chronic hypertension is when hypertension (blood pressure of more than 
140/90 mmHg) is diagnosed preconceptionally or before 20 weeks of gestation 
and remains elevated after 12 weeks postpartum. Naturally, it may either be 
essential hypertension with no underlying cause or secondary hypertension with 
some underlying cause like renal, endocrine or vascular disorders. 
It is termed as Preeclampsia superimposed on chronic hypertension when a 
woman who was previously a hypertensive presents in pregnancy after 20 
weeks with features of preeclampsia such as new-onset proteinuria or even 
worsening of already existing proteinuria/hypertension. 
 
INCIDENCE 
 Hypertensive disorders of pregnancy totally represent about 7 to 15% of 
all pregnancies and makes up about 25% of antenatal admissions1. These also 
account for 16% of maternal mortality worldwide, according to the WHO 
analysis of causes of maternal death2. In India, the prevalence of gestational 
hypertension is around 7.8%3. Describing the trends of maternal mortality in 
United States, in around the year 1930 when the mortality figure was around 
1%, hypertension during pregnancy made a sizable 20% of it. As of now, the 
mortality has dropped down and is around 15/100,000. But hypertension still 
contributes a whopping 10% of these maternal deaths6. Coming to figures from 
UK, hypertensive disorders are the second leading cause maternal mortality and 
make up about one-third of antenatal morbidity7.  
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RISK FACTORS FOR PREECLAMPSIA 
1. Maternal Age 
Increasing maternal age in itself is a risk factor for preeclampsia. The 
incidence of preeclampsia is around 9.4% in women aged above 35 years in 
comparison to the figure of 6.4% in younger women according to the study by 
Lamminpa et al in the year 20128. Of strategic importance is also increasing 
incidence in women of the other extreme of age-the teenagers. The study by 
Robillard and Halsey outline the predisposition of teenagers to develop the 
condition9.   
2. Parity 
Preeclampsia is essentially a disease of first pregnancy. Women who 
have previously had a successful or failed pregnancy are at reduced risk of 
developing preeclampsia. Mac Gillivray reported that primigravidae have 15 
times more chances of developing proteinuria10.  
3. Family history of Preeclampsia 
Genetic inheritance is a key factor to be noted while studying the risk 
factors for preeclampsia. The predisposition to develop preeclampsia which is 
genetically inherited was studied by Chesley and Cooper11. Another study by 
Cincotta et al12 demonstrated that the risk of severe preeclampsia is about four 
times higher in primigravidae with family history. John Studd13 has also pointed 
out that the risk of developing preeclampsia is about 25% and eclampsia is 
about 3% for daughters born to mothers with history of preeclampsia.  
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4. Race and ethnicity 
Excluding the lifestyle, education and other demographic factors, 
ethnicity in itself alone has been found to be a risk factor for developing 
preeclampsia according to Bouthoornsh et al14. 
5. Paternity 
Primipaternity is also considered an important factor in the incidence of 
preeclampsia. Not only is the first pregnancy at increased risk of developing 
preeclampsia, but also the first pregnancy by the current partner has to be taken 
into account according to the study by Deswiet et al15. Paternal risk factor is 
also highlighted by the fact that fathers who have already fathered a 
preeclamptic pregnancy are at nearly twice the risk of again fathering a 
preeclamptic pregnancy with another woman 
6. Obesity 
Obesity remains a risk factor for many afflictions of pregnancy including 
hypertensive disorders of pregnancy. It is believed that with each 5 to 7 kg/m2 
increase in BMI, the risk of developing preeclampsia doubles 
7. Obstetric factors 
The study of preeclampsia risk factors is incomplete without considering 
the other obstetric risk factors that might complicate the pregnancy such as  
• Multiple gestation 
• Preeclampsia/Gestational hypertension in prior pregnancy 
• Hydatidiform mole 
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• Hydrops fetalis 
• Abnormal uterine artery Doppler at 18-24 weeks 
Studies dedicated to twin gestation have been done which indicate the 
increased risk of preeclampsia, which is about 13% when compared to the 5% 
in singleton pregnancy in a study by Sibai et al16. 
 
8. Pre-existing medical disorders 
• Naturally chronic hypertension is an important risk factor for 
developing preeclampsia with an increased risk of 25-50% more 
than normal pregnancies 
• Diabetes mellitus is the next important condition which along with 
gestational hypertension contributes to a combined incidence of 
30% 
• Autoimmune disorders 
• Renal diseases 
• Thrombophilias 
 Antiphospholipid antibody syndrome 
 Factor V Leiden deficiency 
 Activated Protein C resistance 
 Hyperhomocysteinemia  
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9. Placental and Fetal factors: 
Impaired placentation is the most important risk factor for preeclampsia 
which is at the crux of its pathogenesis. Inadequate autophagy and poor 
placentation as causative factors for preeclampsia is explained by Saito et al17. 
In addition as mentioned above, multiple pregnancies is associated with higher 
risk16. Also fetal abnormalities such as hydrops fetalis18, hydatidiform mole, 
trisomies and triploidy and advancing gestational age also contribute to 
increased risk. 
 
ETIOPATHOGENESIS 
 Etiopathogenesis of this common disorder stands elusive in spite of its 
wide prevalence. Several theories have been putforth, none of which is 
completely satisfactory. However, the most widely accepted root cause is that of 
abnormal placentation explained by the Two-Stage Disorder Hypothesis. The 
two stages are: 
• Stage 1: Incomplete migration of the endovascular trophoblastic cells in 
the spiral arteries resulting in decreased uteroplacental perfusion 
• Stage 2: The above explained defective uteroplacental perfusion resulting 
in the maternal syndrome of preeclampsia 
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ABNORMAL PLACENTATION 
 The migration of the endovascular cytotrophoblastic cells into the 
endothelium and smooth muscle layer of spiral arterioles in the placenta is a 
vital event that occurs in normal pregnancies in the first trimester. It is because 
of this important event that the spiral arterioles are converted into low resistance 
channels which is essential for maintaining the vascularity of the placenta. This 
is completed by about mid-pregnancy in the second trimester. 
                             
 In Preeclampsia however, the process is maladapted. The migration that 
takes place in two stages falters in the second stage due to defective 
differentiation of the trophoblasts which succeed in only penetrating the 
endothelium and not the muscle layer. Thus, the spiral arterioles maintain their 
limited caliber. Also they remain responsive to vasomotor influences. 
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 PLACENTAL HYPOPERFUSION AND HYPOXIA 
The above mentioned placental maladaptation obviously leads to placental 
hypoperfusion and hypoxia. In addition, this stage is also further modified by 
other factors that can reduce placental perfusion such as diabetes, connective 
tissue disorders and so on. Thus, the repeated and prolonged drop in placental 
perfusion in turn releases placental debris into the intervillous spaces of 
maternal circulation. These products thus released spike maternal endothelial 
dysfunction. 
ENDOTHELIAL DYSFUNCTION AND VASOSPASM 
 The normal balance between the proangiogenic factors like VEGF 
(vascular endothelial growth factor) and PIGF (placental growth factor) and 
antiangiogenic factors like soluble Fms-like tyrosine kinase-1 (sFlt-1) is 
essential for optimal vascularity in pregnancy. However in case of 
preeclampsia, this balance is tipped in balance of excess antiangiogenic factors 
by the gradual uteroplacental hypoxia. Thus the resultant excessive sFlt-1 is 
responsible for the decreased production of the vasodilatory prostaglandins 
(PGI2) and Nitric oxide which causes vasospasm, the main event behind 
preeclampsia 
Also contributing to endothelial dysfunction is the inflammation caused by 
cytokines like TNFα and Interleukins on the endothelium. These cytokines are 
released by the syncytiotrophoblastic debris of the placenta provoking 
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inflammation. These cytokines cause an oxidative stress by forming free 
radicals.  
The combined effect of endothelial inflammation and drop in the level of 
vasodilators lead to platelet aggregation and vasospasm. Platelet aggregation 
along with microvascular coagulation results in thrombi formation and 
thrombocytopenia. On the other hand, the intense and generalized vasospasm 
leads to increased vascular resistance and decreased organ perfusion which 
leads to necrosis, hemorrhage and other manifestations of end-organ failure. 
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IMMUNOLOGIC FACTORS 
 An immunologic tolerance to the paternal and fetal antigens is very much 
essential in a normal pregnancy in order to facilitate the implantation of 
placenta and further growth of fetus. However due to an error in this immune 
tolerance that occurs in preeclampsia, the normal trophoblastic invasion that 
occurs is error prone and hence predisposed to develop preeclampsia. 
GENETIC FACTORS 
 Genetic predisposition to preeclampsia is a well established one. MTHFR 
gene coding for methylene tetrahydrofolate reductase and Factor V Leiden gene 
have been found to coexist with thrombophilia genes. In addition, the NOS3 
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gene plays an important role in the etiology of preeclampsia since it encodes for 
the placental nitric oxide production which is affected here.  
PATHOLOGY 
HEMODYNAMIC CHANGES 
 The major point to be noted is that the normal increasing cardiac output 
and decreasing peripheral resistance of pregnancy is inverted in preeclampsia. 
With worsening preeclampsia, there is decrease in cardiac output and increase 
in peripheral resistance. Also there is an increased vascular sensitivity to 
vasopressors.  
 The severe vasospasm along with microvascular leak shifts the fluid from 
intravascular to interstitial compartment. This fluid leak along with reduced 
oncotic pressure (caused by proteinuria and resultant protein loss) leads to the 
pathological edema of preeclampsia. In addition, the loss of intravascular fluid 
leads to relative hypovolemia along with hemoconcentration which is the 
trademark of severe preeclampsia. It is this hypovolemia which also contributes 
in the causation of growth restriction, oligohydramnios and preterm labour.  
HEMATOLOGICAL CHANGES 
 The high cardiac output in severe preeclampsia along with the increased 
peripheral resistance causes traumatic lysis of the red blood corpuscles leading 
to microangiopathic hemolytic anemia. The other common hematological 
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abnormality noted is drop in the platelet count; which on exceeding the 
1,00,000/µl mark denotes severe preeclampsia. These both combined together is 
noted in HELLP syndrome, a dreaded complication of preeclampsia. 
 Though thrombocytopenia and consumptive coagulopathy are obvious 
complications noted here, overt coagulation defects are rare and are observed in 
cases of abruption alone. This rules out the need for regular use of coagulation 
investigations like PT, aPTT and plasma fibrinogen in cases of preeclampsia. 
RENAL CHANGES 
 The trademark lesion that is found in preeclampsia is ‘Glomerular 
capillary endotheliosis’ which is nothing but the enlargement of the endothelial 
cells of the glomerular capillaries which is evident on electron microscope. This 
in turn leads to a reduced blood flow and hence glomerular enlargement. The 
reduced renal blood flow in turn leads to drop in glomerular filtration.  
 The proteinuria that typically characterizes preeclampsia is due to 
increased vascular permeability to proteins in the glomeruli. This along with 
drop in glomerular filtration cause increased levels of serum creatinine and uric 
acid levels.  
 In addition, the rennin-angiotensin system gets activated due to the renal 
pathology which in turn leads to sodium and chloride retention.  
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 Acute renal failure (ARF) that occurs in preeclampsia is almost always 
due to acute tubular necrosis (ATN). This occurs whenever there is profuse 
hemorrhage and also hypovolemia and hypotension.   
HEPATIC CHANGES 
 The intense vasospasm in the hepatic sinusoids along with fibrin 
deposition result in infarction and periportal hemorrhages. These hemorrhagic 
infarctions result in the formation of hematoma beneath the Glisson’s capsule, 
the so called subcapsular hematoma.  
 The hematoma thus formed in need of space expands and stretches the 
Glisson’s capsule, thus causing the characteristic epigastric pain of severe 
preeclampsia. In addition, the infarct and cellular damage to hepatic cells cause 
release of hepatic enzymes into the blood, thus elevating the blood levels of 
SGOT and SGPT which also indicates severe preeclampsia.  
  
17 
 
        
 As long as the hemorrhage remains subcapsular, the patient also remains 
hemodynamically stable but in severe pain. But when the hemorrhage is 
combined with DIC, the hemorrhage becomes major and may even lead to liver 
rupture.  
CENTRAL NERVOUS SYSTEM CHANGES 
 The obvious and dreaded neurologic complication of preeclampsia is 
Eclampsia. This occurs in the setting of intense vasospasm leading to ischemia 
and infarction of neurons. Also more than half of eclamptic women have 
intracranial bleed (both cortical and subcortical hemorrhages) which is due to 
uncontrolled hypertension. In addition, the widespread endothelial damage 
causes vascular leak and thus perivascular edema. Thus, the pathology involves 
softening, necrosis, infarct and hemorrhages. Vasospasm occurring in different 
  
18 
 
areas of motor cortex lead to different manifestations: severe headache 
unrelieved by analgesics when frontal area is involved, cortical blindness when 
occipital area is involved and henceforth. Thus control of blood pressure within 
normal limits is very vital to prevent cerebrovascular accidents. Widespread 
cerebral edema also occurs which can manifest as coma and confusion. 
 Eden’s criteria are used for assessing the severity of eclampsia and also 
used as indications for CT scan. They are: 
• Coma of >6 hours 
• Temperature > 390 C 
• Pulse rate > 120/min 
• Systolic BP >200 mmHg 
• Respiratory rate >40/min 
• More than 10 convulsions 
PLACENTAL CHANGES 
 The basic underlying pathology of incomplete trophoblastic invasion that 
occurs in the placenta is responsible for the placental changes in preeclampsia 
which occur even before the clinical manifestations are evident. The narrow and 
necrosed spiral arteries along with the compromised uterine blood flow are the 
main culprits in causing fetal growth restriction and preterm labour. 
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 Also characteristic changes in the placenta include increased apoptosis 
and necrosis of syncytiotrophoblast. Thus, increased syncytial knots, 
cytotrophoblastic proliferation, fibrinoid necrosis and calcified and hyalinised 
villi are the findings observed under microscopy19.   
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PREDICTIVE TESTS FOR PREECLAMPSIA: 
CLINICAL HISTORY 
 Detailed clinical history taken at the time of antenatal booking serves as 
the first step in evaluating a patient for preeclampsia. The points that raise 
suspicion in favour of preeclampsia include advancing maternal age, 
primiparity, primipaternity, multiple gestation, a previous history of 
preeclampsia, antiphospholipid antibodies and so on. These risk factors already 
discussed above along with routine measurement of blood pressure in clinical 
visits help in clinching an early diagnosis20. 
CLINICAL TESTS 
 Mean Arterial Pressure of more than 90 mmHg measured in the second 
trimester is predictive of preeclampsia since this value normally drops at this 
point of time. MAP is calculated from diastolic and pulse pressure. Though the 
sensitivity of mean arterial pressure is very low21 in the range of 0-9%, its 
specificity is comparatively high in the range of 53-97%. This is the initial step 
in predicting preeclampsia.  
 Roll over test which is done between 28 to 32 weeks is a routine test 
which is recommended for the early diagnosis of gestational hypertension22. 
This test involves determining the difference in blood pressure that is noted 
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when the patient is in supine position and she rolls over to left lateral position. 
A difference in diastolic pressure of more than 20 mmHg is considered positive. 
 Hand grip test is another test which is advocated for predicting 
preeclampsia. It involves maintaining the pressure at 200 mmHg for 3 mins by 
holding the BP cuff in the hand. Later, the diastolic pressure is reassessed. A 
rise of more than 20 mmHg is considered positive. The sensitivity of the test in 
prediction of preeclampsia is around 80% while the specificity is 92%23. 
However the test is found unsuitable when employed as a screening test because 
of its time consuming nature. It is limited to research purposes.  
BIOCHEMICAL PARAMETERS 
 When microalbuminuria is detected around 18 weeks by measuring urine 
albumin excretion of more than 30 mg in 24 hours, it can serve as an excellent 
predictor of preeclampsia that is about to subsequently develop24. 
 Reduced levels of urate excretion leads to raised serum uric acid levels. 
Plasma uric acid level of more than 5.9 mg/dl measured at around 24 weeks has 
a positive predictive value of preeclampsia of around 33 percent according to 
study by Jacobson and colleagues (1990).  
 Even in the presence of normal uric acid levels, when plasma urea and 
creatinine values are raised, they denote renal impairment and also in a way 
predict preeclampsia, though they have a low predictive value.  
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 Hypocalciuria of less than 195 mg per 24 hours is found to be a predictor 
of preeclampsia in later pregnancy according to Maikranz et al25. 
 When the calcium creatinine ratio is measured, it is around 0.44 ± 0.32 in 
normotensive women. However the value drops and it is around 0.03 in 
preeclamptic women and 0.20 in chronic hypertensive women. Thus, a ratio of 
less than 0.06 can be said to be strongly indicative of preeclampsia. However 
this has a false positive rate of around 33% according to Saudan et al26. 
 Also, plasma fibronectin is found to be elevated in women with 
preeclampsia and eclampsia as early as first trimester itself according to a study 
by Ballegeer et al27.  
 When inactive urinary Kallikrein to creatinine ratio is measured in a 
random urine sample which is collected between 16 to 20 weeks of pregnancy, 
it is found to have a predictive value in the diagnosis of preeclampsia28. 
 Since nitric oxide is implicated in the pathogenesis of preeclampsia, when 
its metabolites such as nitrite/nitrate are measured in urine, their total urinary 
excretion can give an idea about the severity of preeclampsia according to the 
study by Begum et al29. 
HEMATOLOGICAL TESTS 
 As discussed in the pathology of preeclampsia, hematological alterations 
that occur in preeclampsia can be measured. Such tests include platelet count, 
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hematocrit, hemoglobin levels, RBC morphology and coagulation profile. Also, 
D-dimer and Antithrombin 3 levels are also measured in patients with 
preeclampsia. However, the test that is believed to have some predictive value is 
that of serum ferritin since hyperferritinemia is considered to be a result of 
placental damage.  
PRESSOR RESPONSE TEST 
 As already discussed in etiopathogenesis, in addition to the abnormal 
placentation in preeclampsia, the spiral arterioles also retain their response to 
the vasopressor agents. Hence, Angiotensin Sensitivity Test (AST) where we 
look for the dose of infused Angiotensin II that raises the BP by 20 mmHg is 
thought to be a better predictor of PIH. The specificity of the test is 85% though 
the sensitivity is only 22%27. 
HORMONAL TESTS 
 Hyperprolactinemia is an important criterion to be considered while 
predicting the risk of developing preeclampsia. Both the blood pressure and 
prolactin secretion are influenced by diminished dopaminergic activity in the 
CNS30. 
UTERINE ARTERY DOPPLER VELOCIMETRY 
 However when compared to all the above, the test which is of clinical 
importance today is Uterine artery Doppler which is commonly done in second 
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trimester. Even in early gestation, a drop in the flow of uterine artery can be 
picked up by Doppler velocimetry. The presence of diastolic notching and a 
high resistance or pulsatility index or S/D ratio is suggestive of impaired blood 
flow31. However more than predicting preeclampsia, they are more useful in 
predicting fetal growth restriction.  
NEWER MARKERS 
 Newer biochemical markers such as ADAM 12, free β-hCG, Inhibin A, 
Activin A, PP13, PIGF, PAPP-A, sFlt-1, P-selectin performed in the first 
trimester have shown to have a predictive value for preeclampsia. These along 
with Uterine artery Doppler are promising recent trends32 
LABORATORY INVESTIGATIONS: 
• Complete Blood Count and blood film 
• Blood urea and creatinine 
• Serum uric acid 
• Liver function tests 
• Urine Albumin and Sugar 
• Serum electrolytes 
• Coagulation profile 
• 24 hour urinary protein 
• Lactate dehydrogenase 
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• Creatinine clearance 
• Antiphospholipid antibodies 
• Fundus opinion 
• Obstetric Ultrasound with Doppler 
• Plasma and urinary metanephrines 
• Serum renin and aldosterone levels 
• Electrocardiogram 
PREVENTION OF PREECLAMPSIA: 
Diet and Supplementation: Although it has been publicized that salt 
restriction, antioxidants, marine oils, proteins, magnesium supplementation and 
folic acid have a role in preventing preeclampsia, trials have failed to establish a 
concrete proof for the same.  
 According to the study by Hofmeyr et al33, preeclampsia incidence can be 
reduced to half by supplementing 1.5-2 g of calcium carbonate or elemental 
calcium; especially for high risk women and those with low calcium intake. 
 Since L-Arginine is the precursor of vasodilator Nitric Oxide, it is 
naturally expected that supplementation of L-Arginine might reduce the 
incidence of preeclampsia. But again, this point lacks proof from studies. 
 Antioxidants such as Vit C and Vit E are expected to limit the oxidative 
stress, prevent endothelial injury and hence reduce the incidence of 
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preeclampsia. However, studies have shown little benefit and even benefit for 
harm.    
Exercise  
Though exercise and physical activity are very much linked with reduced 
incidence of hypertension in non-pregnant population, prospective population 
based studies have failed to establish a link between exercise and incidence of 
preeclampsia34. 
Low Dose Aspirin 
National Institute of Clinical Excellence, UK35 places a recommendation 
of low dose supplementation of Aspirin (75 mg) daily for high risk women in 
order to prevent preeclampsia. This suppresses the thromboxane synthesis in 
platelets and prevents microthrombi formation.  
 CLASP (Collaborative Low Dose Aspirin Study in Pregnancy), a large 
randomized controlled trial done in this respect showed a reduction of about 
12% in the incidence of preeclampsia with low dose aspirin36.  
 But, a significant reduction in the incidence of preeclampsia of about 
50% was noted by Bujold et al when he started low dose aspirin before 16 
weeks of gestation37. 
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MANAGEMENT OF HYPERTENSION DURING PREGNANCY 
ANTIHYPERTENSIVE DRUGS 
1. Labetalol 
This combined alpha and beta blocker drug is now the preferred first line 
therapy in the treatment of preeclampsia. The onset of action of the drug is 5 to 
10 mins 
Orally, the dosage of the drug is 100-400 mg twice daily for mild 
preeclampsia. The maximum dose of the drug is 1200 mg. In case of severe 
hypertension (BP>160/110 mmHg), intravenous route of the drug is given. It is 
started as an IV bolus of 10-20 mg. This is then followed up with 20-80 mg IV 
dose every 30 mins until we reach the maximum dose of 300 mg. 
The drug is attractive in the fact that the decline of blood pressure is rapid 
but smooth and also there is no adverse effect on the fetal circulation. Also the 
drug rarely causes maternal hypotension and tachycardia. 
But, caution has to be exercised in patients with asthma and congestive 
heart failure where it is preferable to avoid this drug 
2. Nifedipine 
This calcium channel blocker is the next drug of choice in the treatment 
of preeclampsia. The onset of action is 10 to 15 mins 
The drug is given at a dose of 10-20 mg twice or thrice daily with the 
maximum dose being 180 mg per day.  
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Short acting Nifedipine is appealing in the fact that it gives a more rapid 
control of hypertension when compared with labetalol. Hence it is effective in 
the acute treatment of severe hypertension in pregnancy. However as with other 
antihypertensives, it causes maternal hypotension in addition to causing fetal 
distress. 
3. Alpha Methyl Dopa 
Alpha Methyl Dopa is a centrally acting Alpha adrenergic agonist which 
inhibits adrenergic receptors in the vasomotor center. When the drug is given 
orally, it takes 3-6 hours to act. It acts by decreasing cardiac output, peripheral 
resistance and renal blood flow. 
The dosage of the drug is 250-500 mg twice or thrice daily to a maximum 
of 2g per day. 
While sedation and fatigue are the common side effects, it also causes 
altered liver function tests, skin rash and cholestatic jaundice 
4. Hydralazine 
This drug acts by directly causing relaxation of the smooth muscles of 
the arterioles and venules. Onset of action is from 10 to 20 mins. 
An intermittent bolus of 5 mg IV once in about 30 mins or an infusion at 
the rate of 0.5-10 mg per hour is the route in which the drug is given. The 
maximum dose of the drug is 30 mg. 
In spite of the long experience of the drug in clinical setting, its 
disadvantage lies in the fact that its adverse effects like severe headache (due to 
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raised intracranial pressure) often mimic the features of severe preeclampsia. 
Also fetal heart monitoring reveals signs of abnormal fetal heart pattern in 
addition to low one-minute Apgar scores. Hydralazine is also known to cause 
maternal hypotension, placental abruption, caesarian section and oliguria38. 
5. Sodium Nitroprusside 
This is a short acting antihypertensive which relaxes both venous and 
arteriolar smooth muscles. Onset of action of the drug is less than one minute 
and its duration is limited to 1 to 3 minutes and hence the drug is valuable in its 
use in Hypertensive Emergencies. 
The drug is given intravenously at the rate of 0.25 µg/kg/min. The 
maximum dose tolerated is 8 µg/kg/min.  
MANAGEMENT OF GESTATIONAL HYPERTENSION 
• Gestational hypertension is managed as outpatient with the patient 
coming for weekly antenatal visit during which we look for blood 
pressure, proteinuria, signs of preeclampsia, platelet count and liver 
enzymes.   
• The patient is advised daily fetal movement monitoring/fetal kick count 
to which is added biweekly non-stress test and biophysical profile. 
• Fetal growth monitoring is done once in 3 weeks 
• Antihypertensives are given when pressure exceeds 150/100 mmHg 
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• Severe gestational hypertension is when pressure is more than 160/110 
mmHg but without proteinuria. Such patients are managed as like severe 
preeclampsia 
 
MANAGEMENT OF MILD PREECLAMPSIA 
• Patients with mild preeclampsia are hospitalized and monitored for BP, 
proteinuria and signs and symptoms of severe preeclampsia. 
• A reduced level of physical activity with 4-6 hours of bed rest in a day is 
advised to halt the progression to severe preeclampsia.  
• In addition to the daily fetal movement monitoring, weekly NST and 
biophysical profile and fetal growth monitoring once in 2-3 weeks is 
recommended. 
• Antihypertensive drugs are given to retain the BP within normal limits 
and this also decreases the risk of developing severe preeclampsia by 
half39. 
Timing of 
delivery
BP<150/100 
mmHg
39-40 weeks
BP between 
150/100 and 
160/110 mmHg
37-38 weeks
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• Since prolonging the pregnancy beyond 37 weeks only increases the risk 
of progression to severe preeclampsia, mild preeclampsia is generally 
terminated at 37 weeks of gestation 
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MANAGEMENT OF SEVERE PREECLAMPSIA 
 The definitive management of severe preeclampsia lies in delivering the 
fetus and placenta. But when in early gestation, the risk of delivering a preterm 
neonate has to be weighed against the risk of continuing the pregnancy. 
Expectant Management 
• Prolongation of the pregnancy up to 34 weeks though of no benefit to the 
mother with even a slight complication rate of 5% improves fetal 
survival chances 
• This has to be undertaken only in a tertiary care centre with neonatal 
intensive care facilities 
• 4th hourly BP monitoring, strict input-output chart, daily urine protein are 
to be undertaken along with appropriate oral antihypertensives 
• Twice weekly maternal blood count, liver and renal function tests are 
done 
• Close fetal monitoring with daily fetal kick chart and biweekly NST and 
biophysical profile are done 
• Elective delivery is undertaken at 34 weeks by vaginal delivery; resorting 
to caesarean route only when obvious obstetrical indications are present  
Criteria for termination of pregnancy in Severe Preeclampsia 
The expectant management is abandoned and pregnancy terminated when the 
following indications are present40: 
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• Persistent severe hypertension unresponsive to medical therapy 
• Imminent symptoms such as persistent headache, blurring of vision, right 
upper quadrant pain and decreased urine output.  
• Eclampsia 
• Thrombocytopenia (<1,00,000/mm3) 
• Suspected abruption placenta 
• Progressive decline in hepatic and renal function 
• Severe intrauterine growth restriction 
• Non reassuring fetal heart rate  
• Oligohydramnios 
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Once the patient is stabilized, close fetal surveillance and delivery is effected 
when the gestational age crosses 34 weeks. 
MANAGEMENT OF ECLAMPSIA 
Management of Eclampsia is a 3 pronged approach: 
➢ Control of convulsions 
➢ Control of hypertension 
➢ Termination of pregnancy 
Anticonvulsant therapy 
• Initial steps of management include placing the patient in left lateral 
position, providing a mouth gag and using mouth suction to remove 
secretions and vomitus. Vitals are then monitored. Oxygen at the rate of 
8-10 l/min is given to correct maternal and fetal hypoxia. If needed, IV 
fluids are administered but with caution lest pulmonary edema should 
occur. 
• Magnesium Sulphate is the drug of choice for eclampsia. This drug which 
has a central anticonvulsant and neuroprotective effect without causing 
sedation or CNS depression in the mother and fetus. Maternal mortality is 
nearly halved in women who receive Magnesium sulphate41. 
• Pritchard’s regime is the preferred protocol which is being followed. 
The initial loading dose is 4g (20 ml of 20% MgSO4) which is given as 
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slow IV over 4 mins which is immediately followed by 10g (20 ml of 
50% MgSO4) deep IM which is split as 5g in each buttock. The 
maintenance dose is 5g (10 ml of 50% MgSO4) given as deep IM every 4 
hours in alternate buttocks. 
• The patients on Magnesium Sulphate are to be monitored periodically 
before each dose. Respiratory rate of more than 20/min, presence of 
patellar reflex and urine output of at least 100ml in 4 hours should be 
ensured; the absence of which denotes magnesium toxicity.  
• The regime is given until 24 hours after delivery or 24 hours after the last 
seizure, whichever is later.   
• Since the drug is excreted by kidneys, renal dysfunction warrants dosage 
adjustment. Also careful monitoring is needed to pick up magnesium 
toxicity and the therapeutic levels lie between 5-7 mEq/L. If at all 
magnesium toxicity occurs, the antidote is calcium gluconate which is 
given as 1g IV.  
• Magnesium Sulphate also causes loss of variability in fetal heart rate 
which is clinically insignificant. 
• Other regimens used though unpopular are Sibai regime, Zuspa regime, 
Cruikshank regime, Low dose regime of Sardesai and Sokoto regime.  
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• Though several other drugs like diazepam, phenytoin and lytic cocktail 
were initially advocated as alternatives for Magnesium Sulphate, these 
are not recommended now40. 
Antihypertensive therapy 
 Immediate control of blood pressure is warranted for which oral 
Nifedipine,  IV  labetalol or even IV hydralazine are employed 
 
Obstetric management 
• Occurrence of seizure causes fetal heart rate changes which recover after 
the episode of seizure. The woman may also be in labour. Hence, 
artificial rupture of membranes along with oxytocin is sufficient.  
• If the patient is not in labour, the favorability of cervix is noted along 
with the fetal wellbeing. Then decision is taken regarding prostaglandin 
use to ripen the cervix or emergency shifting of patient for Caesarean 
section. 
 
MATERNAL COMPLICATIONS 
• Eclampsia is the feared complication 
• Cerebral edema and cerebrovascular accidents 
• Placental abruption is an important complication that can be fatal for both 
mother and fetus 
• Pulmonary edema with or without left ventricular failure 
• Microangiopathic hemolytic anemia 
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• Acute renal failure 
• HELLP syndrome: 
This well known complication of preeclampsia generally presents 
in the third trimester with an incidence of about 0.8% of all pregnancies42. The 
presence of hemolysis requires a low hematocrit, elevated bilirubin, elevated 
LDH (>600 IU/L) and a peripheral smear showing reticulocytes, spherocytes 
and schizocytes for confirmation. Along with these, we also require the 
evidence of elevated liver enzymes (AST and ALT) and low platelets to 
establish the diagnosis. 
The 3 classes of HELLP syndrome are classified based on platelet 
counts as: Class I with platelets <50,000/mm3, Class II with counts between 
50,000 to 1,00,000 and Class III with platelets between 1,00,000 and 
1,50,000/mm3. Partial HELLP syndrome is a category when all the three 
abnormalities of HELLP (namely hemolysis, elevated liver enzymes and low 
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platelets) are not present together with one or two lacking.                   
 
When the diagnosis is established, platelet count and lactate 
dehydrogenase levels are the reliable parameters in tracking the disease status. 
These begin to normalize within 72 hours of delivery. Corticosteroids are given 
for fetal pulmonary maturity. In addition, high dose of dexamethasone (10mg 
IV 12th hourly) when given is found to enhance the laboratory abnormalities43.  
 
FETAL COMPLICATIONS 
• Intrauterine growth restriction is an important complication as a result of 
drop in placental blood flow. Nearly 20% of the preterm babies and 15% 
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of the term babies born to preeclamptic mothers are SGA babies with 
birth weights less than the 10th centile.  
• Prematurity is another well known complication with nearly half of all 
mothers with severe preeclampsia delivering preterm. Point also to be 
noted is that out of total preterm births, about 10% are the preterm births 
resulting from hypertensive disorders of pregnancy 
• Birth asphyxia  
• Intrauterine deaths 
• Stillbirths are an important problem with hypertensive disorders being the 
foremost identifiable cause of stillbirths44.   
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AIM OF THE STUDY 
1. To study the demographic profile; risk factors, prevalence and 
epidemiological parameters of antenatal mothers presenting with 
hypertension during pregnancy 
2. To determine the incidence of the different hypertensive disorders of 
pregnancy and study its pattern of occurrence 
3. To assess the maternal and fetal outcome in pregnancies complicated with 
hypertension 
4. To study the maternal and perinatal mortality and morbidity 
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MATERIALS AND METHODS 
STUDY DESIGN 
 Descriptive study 
STUDY SETTING 
 Department of Obstetrics and Gynaecology, Chengalpattu Medical 
College, Chengalpattu 
STUDY PERIOD  
 October 2016 - September 2017 
SAMPLING SIZE  
Hypertensive pregnant women attending hospital during study period. 
INCLUSION CRITERIA 
• All pregnant women diagnosed with pregnancy induced hypertension 
based on the criteria defined by the working of the NHBPEP (National 
high blood pressure education programme) 
• Gestational hypertension or pregnancy induced hypertension. 
• Pre-eclampsia- eclampsia 
• Chronic hypertension  
• Pre-eclampsia superimposed on chronic hypertension 
EXCLUSION CRITERIA 
• Multiple pregnancy 
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• Major fetal anomaly, incompatible with survival 
• Patients who were diagnosed with other causes of convulsions in 
pregnancy like cerebral malaria and epilepsy. 
• Pregnancies complicated with diabetes mellitus, primary renal disease and 
collagen vascular diseases. 
CASE DEFINITION 
 All clinically diagnosed cases of gestational hypertension with further 
classification based on the biochemical investigations 
ETHICAL CONSIDERATIONS 
 Ethical clearance was obtained from the Institutional Ethical Committee. 
Informed written consent was obtained from the patients of study group. Strict 
confidentiality was maintained throughout the study 
STUDY MANOUEVRE 
• All the pregnant women coming to the Antenatal OPD and Obstetric 
casualty were screened for hypertension and its complications. Blood 
pressure was measured in the sitting position in the right upper limb using 
mercury sphygmomanometer with arm at the level of heart. An 
appropriate bladder cuff was used which encircles two-thirds of the arm. 
Blood pressure value of more than 140/90 mmHg was followed up with 
another reading at an interval of 6 hours. Diagnosis was based on 
NHBPEP guidelines4.    
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• After carefully considering the inclusion and exclusion criteria, 450 
women were selected for the study and were followed up throughout their 
gestation and until 2 weeks post delivery. 
• Though patients were hospitalized in majority of cases, in selected cases 
(gestational hypertension, mild pre-eclampsia, chronic hypertension with 
regular blood pressure measurements) at the request of the patient, 
ambulatory control was allowed 
• Demographic data needed for the study such as age, parity, 
socioeconomic status, booking status and residential area were collected 
by careful history taking. These along with the clinical data, laboratory 
results, delivery details and maternal and fetal outcomes was made note 
of in the pre-tested check list proforma. 
• On admission, a thorough clinical examination was made including 
general physical examination, build, nutritional status, height, weight, 
BMI, blood pressure and pulse along with presence or absence of pallor 
and pedal edema. Weight gain during pregnancy was noted. CVS and RS 
were examined.  
• Abdominal examination was done to determine the uterine height (in 
weeks), fetal lie, presentation, and fetal heart rate.  
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• Blood pressure monitoring was done twice daily for all patients with 
more frequent measurements (4th hourly) for those with elevated blood 
pressure.  
• Daily urine albumin was monitored with the help of dipsticks supported 
by laboratory urine analyses. 
 
• The patients were watched for the presence of symptoms of severe 
preeclampsia such as severe headache, blurring of vision, oliguria and 
epigastric pain. Based on all these data, patients were classified into one 
of the following five classes of hypertension based on NHBPEP 
guidelines: 
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• Blood was collected and sent for investigations such as Complete Blood 
Hemogram, Liver Function tests, Renal Function tests and Serum uric 
acid. Urine was sent for urine albumin and sugar determination for all 
patients. 
• Other investigations include coagulation profile, bleeding and clotting 
time, ECG, 24 hour urinary protein. The normal values for these 
investigations include: 
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            PARAMETER NORMAL VALUES 
Hemoglobin 12-16 g/dl 
Hematocrit 32-36% 
Platelet count 1.5-4 lakhs/cu.mm 
Total Bilirubin 0.2-1 mg/dl 
Indirect Bilirubin 0.1-1.0 mg/dl 
Direct Bilirubin 0-0.2 mg/dl 
AST/SGOT 5-43 U/L 
ALT/SGPT 5-56 U/L 
LDH <600 U/L 
Serum uric acid 3-7 mg/dl 
Blood urea 10-15 mg/dl 
Creatinine 0.7-0.9 mg/dl 
PT 12-16 sec 
Fibrinogen 300-600 mg% 
Bleeding Time 1-3 min 
Clotting Time 3-7 min 
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• All patients were sent for an Ophthalmic examination to study  the fundus 
and to screen for hypertensive retinopathy 
 
• Fetal status was evaluated with daily fetal kick chart, biweekly Non 
Stress Test and fortnightly USG evaluation along with Uterine Artery 
Doppler (to rule out IUGR). 
• Decision regarding the line of management of the patient was undertaken 
taking into consideration all of the above factors. 
• Further, the patient was followed up until 2 weeks after delivery to 
determine the time of return of blood pressure to baseline in addition to 
following up the neonate for its outcome. 
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STATSTICAL ANALYSIS 
• Primary data was entered in MS Excel and analyzed using SPSS 20v. 
• The results were presented in terms of tables and graphs. 
• The descriptive statistics frequency and percentage were calculated. 
• The association between the categorical variables were analyzed by 
chi square test with 5% level of significance.     
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RESULTS AND ANALYSIS 
 
According to our study, the distribution of various types of hypertensive 
disorders complicating pregnancy in Chengalpattu Medical College Hospital 
during our study period of one year from October 2016 to September 2017 is: 
TABLE 1 
TYPES OF HYPERTENSION 
 
TYPE OF HYPERTENSION 
NO OF 
PATIENTS PERCENTAGE 
Gestational HT 78 17.3% 
Mild Preeclampsia 125 27.8% 
Severe Preeclampsia 178 39.6% 
AP Eclampsia 52 11.6% 
IP Eclampsia 1 0.2% 
PP Eclampsia 11 2.4% 
Chronic HT 5 1.1% 
Total 450 100% 
 
Out of 450 hypertensive pregnancies, the majority were Severe 
Preeclampsia (39.6%). There were 78 women with Gestational Hypertension 
(17.3%), 125 women with Mild preeclampsia (27.8%), 178 women with Severe 
Preeclampsia (39.6%), 64 women with Eclampsia out of which 52 were AP 
Eclampsia (11.6%), 1 case was IP Eclampsia (0.2%) and 11 women were PP 
Eclampsia (2.4%). 5 women were Chronic hypertensives (1.1%) 
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FIGURE 1 
TYPES OF HYPERTENSION 
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TABLE 2 
AGE DISTRIBUTION 
Age 
No of 
Patients Percentage 
up to 20 yrs 95 21.1 
21-25 Years 233 51.8 
26 - 30 Years 103 22.9 
31 - 35 Years 16 3.6 
> 36 years 3 0.6 
Total 450 100 
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TABLE 3 
AGE DISTRIBUTION IN TYPES OF HYPERTENSION 
Age in 
years 
Gestational 
HT 
Mild 
Preeclampsia 
Severe 
Preeclampsia 
Eclampsia 
Chronic 
HT 
Total 
<=20 13 24 38 20 0 
95 
(21.1%) 
21-25 46 67 88 32 0 
233 
(51.7%) 
26-30 16 30 44 11 2 
103 
(22.9%) 
31-35 3 2 7 1 3 
16 
(3.6%) 
>=36 0 2 1 0 0 
3 
(0.7%) 
Total 78 125 178 64 5 450 
 
Chi- Square value : 62.64     P value : 0.001 
    Statistically significant 
Out of 450 patients, maximum patients (233) fall under the age group of 
21-25 years (51.7%). All the forms of hypertension except Chronic 
hypertension most commonly occur in the 21-25 years group. Chronic 
hypertensives are more common in the 31-35 age group. The next common age 
group is that between 26-30 years with 103 patients (22.9%). The least common 
age group is above 36 years (0.7%). 
 
  
53 
 
FIGURE 3 
AGE DISTRIBUTION IN TYPES OF HYPERTENSION 
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TABLE 4 
GRAVIDA STATUS 
Gravida Number Percentage 
Primi 273 60.7% 
G2 123 27.3% 
G3 & above 54 12.0% 
Total 450 100% 
 
 
 
FIGURE 4 
GRAVIDA STATUS 
 
 
Primi, 273
G2, 123
G3 & above, 54
  
55 
 
TABLE 5 
GRAVIDA STATUS IN HYPERTENSIVE TYPES 
 
Chi-Square value: 21.32           P value: 0.02 
Statistically significant 
 Out of 450 patients, primigravida were the most common (60.7%) in all 
forms of hypertension except in chronic hypertension. The rest are the 
multigravida (39.3%) of which the second gravida are most common.  
 In Gestational hypertension, the most common were primigravida 
(55.1%) followed by second gravida (32.1%). In Preeclampsia, the most 
common were primigravida (56.8%) followed by second gravida (31.2%). In 
Severe Preeclampsia also the most common are primigravida (63.5%). In 
Eclampsia, the most common were primigravida (70.3%) followed by second 
gravida (23.4%) and the least common were third gravida and more (6.3%). 
However in Chronic hypertension, second gravida and higher gravida are 
equally common (40% each) with primi being the least common (20%). 
Gravida 
Gestational 
HT 
Preeclampsia 
Severe 
PE 
Eclampsia 
Chronic 
HT 
Total 
Primi 
43 
(55.1%) 
71 
(56.8%) 
113 
(63.5%) 
45 
(70.3%) 
1 
(20%) 
273 
(60.7%) 
G2 
25 
(32.1%) 
39 
(31.2%) 
42 
(23.6%) 
15 
(23.4%) 
2 
(40%) 
123 
(27.3%) 
G3 & above 
10 
(12.8%) 
15 
(12%) 
23 
(12.9%) 
4 
(6.3%) 
2 
(40%) 
54 
(12%) 
Total 78 125 178 64 5 450 
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FIGURE 5 
GRAVIDA STATUS IN HYPERTENSION TYPES 
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TABLE 6 
SOCIOECONOMIC STATUS 
 
Socioeconomic Status Number Percentage 
I Nil Nil 
II Nil Nil 
III Nil Nil 
IV 83 18.4 
V 367 81.6 
Total 450 100 
 
 Out of 450 patients studied, the majority belonged to the Socioeconomic 
Class V (81.6%) while the rest belonged to Class IV (18.4%). No patients 
belonging to Socioeconomic Class I, II and III took part in the study 
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FIGURE 6 
SOCIOECONOMIC STATUS 
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TABLE 7 
GESTATIONAL AGE AT DELIVERY 
 
 In both Gestational hypertension and Mild Preeclampsia, majority were 
terminated at term (92.3% and 84.8% respectively); while the rest were 
terminated between 35-37 weeks.  
 However the figure is reversed in case of Severe Preeclampsia and 
Eclampsia where majority were terminated before term. In case of Severe 
Preeclampsia, majority were terminated between 35 and 37 weeks of gestation 
(47.2%). Next commonly women delivered at term (23.6%). 
 In case of Antepartum Eclampsia, majority of women delivered between 
35 and 37 weeks (34.6%) while next commonly, women delivered between 29 
and 34 weeks of gestation (32.7%). AP Eclamptic women delivering at term 
Gestational 
Age 
Gestational HT 
Mild 
Preeclampsia 
Severe 
PE 
AP 
Eclampsia 
PP & IP 
Eclampsia 
Chronic 
HT 
Total 
<=28 0 0 
21 
(11.8%) 
3 
(5.8%) 
0 0 
24 
(53.3%) 
29-34 0 0 
31 
(17.4%) 
17 
(32.7%) 
0 0 
46 
(10.2%) 
35-37 
6 
(7.7%) 
19 
(15.2%) 
84 
(47.2%) 
18 
(34.6%) 
6 
(50%) 
3 
(60%) 
91 
(20.2%) 
>37 
72 
(92.3%) 
106 
(84.8%) 
42 
(23.6%) 
14 
(26.9%) 
6 
(50%) 
2 
(40%) 
289 
(64.2%) 
Total 78 125 178 52 12 5 450 
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were less common (26.9%). In case of intrapartum and postpartum eclampsia, 
delivery around 29-34 weeks and 35-37 weeks were equally common.  
 Of the chronic hypertensives, 3 delivered between 29 and 34 weeks and 2 
delivered between 35 and 37 weeks. 
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TABLE 8 
MODE OF DELIVERY 
 
 
 
 
FIGURE 8 
MODE OF DELIVERY 
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TABLE 9 
MODE OF DELIVERY IN HYPERTENSION TYPES 
Mode of 
Delivery 
Gestational 
HT 
Mild 
Preeclampsia 
Severe 
PE 
Eclampsia 
Chronic 
HT 
Total 
Labour 
Natural 
37 
(47.4%) 
61 
(48.8%) 
63 
(35.3%) 
15 
(23.4%) 
1 
(20%) 
177 
(39.3%) 
Assisted 
delivery 
9 
(11.5%) 
11 
(8.8%) 
0 0 0 
20 
(4.4%) 
Hysterotomy 0 0 0 
4 
(6.2%) 
0 
4 
(0.9%) 
Spontaneous 
expulsion 
0 0 
21 
(11.8%) 
3 
(4.7%) 
0 
24 
(5.4%) 
LSCS 
32 
(41.1%) 
53 
(42.4%) 
94 
(52.9%) 
42 
(65.7%) 
4 
(80%) 
225 
(50%) 
Total 78 125 178 64 5 450 
 
 Out of 450 patients, about half delivered by LSCS method (50%) while 
the next common method of delivery was by Labour natural (39.3%). There 
were only four cases of hysterotomy (0.9%) which was the least common. 
 In Gestational hypertension, majority delivered by Labour natural 
(47.4%) while LSCS was the next common option of delivery (41.1%). In Mild 
Preeclampsia also, Labour Natural remained the most common mode of 
delivery (48.8%) while the next in line was LSCS (42.4%) 
 In Severe Preeclampsia however, the common mode of delivery was 
LSCS (52.9%) which is followed by Labour Natural (35.3%). In Eclampsia too, 
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LSCS was the common method to deliver (65.7%) and Labour Natural the next 
common method (23.4%).  
 In Chronic Hypertensives, 80% delivered by LSCS & 20% by Labour 
Natural. 
 
 
FIGURE 9 
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TABLE 10 
MATERNAL COMPLICATIONS 
Complication Number Percentage 
Eclampsia 64 14.2% 
Abruptio placenta 51 11.3% 
HELLP 8 1.8% 
PPH 27 6% 
DIC 7 1.6% 
ARF 6 1.3% 
CVA 9 2% 
Pulmonary edema 2 0.4% 
Retinopathy 1 0.2% 
Maternal Death 3 0.6% 
 
 
FIGURE 10 
MATERNAL COMPLICATIONS 
 
 
 
51
8
27
7
6
9
2 1 3 Abruptio placenta
HELLP
PPH
DIC
ARF
CVA
Pulmonary edema
Retinopathy
Maternal Death
  
65 
 
TABLE 11 
MATERNAL COMPLICATIONS IN HYPERTENSION TYPES 
  
Out of the total complications, majority occurred in patients with Severe 
Preeclampsia and Eclampsia. About 353 patients sustained an uneventful 
pregnancy without any complications (78.4%).  
 Out of 450 patients, 51 developed Abruptio placenta (11.3%) and 9 
developed Cerebrovascular accidents (2%) which includes cases with CT 
features suggestive of PRES. 8 mothers developed HELLP syndrome (1.8%) 
and 6 women developed Acute Renal Failure (1.3%). PPH occurred in 27 
women (6%).  
Maternal 
Complications 
Gestational 
HT 
Mild 
Preeclampsia 
Severe 
PE 
Eclampsia 
Chronic 
HT 
Total 
Maternal Death 0 0 1 2 0 
3 
(0.6%) 
ARF 0 0 2 4 0 
6 
(1.3%) 
Abruptio placenta 0 9 37 5 0 
51 
(11.3%) 
DIC 0 0 6 1 0 
7 
(1.6%) 
CVA 0 0 0 9 0 
9 
(2%) 
HELLP 0 0 6 2 0 
8 
(1.8%) 
PPH 1 6 19 1 0 
27 
(6%) 
Pulmonary edema 0 0 1 1 0 
2 
(0.4%) 
Retinopathy 0 0 1 0 0 
1 
(0.2%) 
Total 1 15 73 25 0 114 
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TABLE 12 
POSTPA RTUM RETURN OF BLOOD PRESSURE TO BASELINE 
HYPERTENSION 
TYPE 
0-2 DAYS 3-13 DAYS 
2 WEEKS AND 
ABOVE 
GESTATIONAL HT 75 3 - 
PREECLAMPSIA 102 14 7 
SEVERE 
PREECLAMPSIA 
8 92 57 
ECLAMPSIA - 29 27 
TOTAL 185 138 91 
PERCENTAGE 41.1 20.7 20.2 
 
 Out of 450 women studied, 33 women did not achieve postpartum return 
of Blood Pressure value to baseline within the period followed up and were 
discharged with antihypertensives. These 33 women also include the 5 chronic 
hypertensives. Excluding the 3 maternal deaths, the rest 414 women had their 
pressure values returned to baseline.  
 Majority of these women became normotensive within the first two days 
of delivery (41.1%). The next major group had normal pressure values within 
13 days (20.7%) closely followed by those who took 2 weeks and more to 
return to the normal blood pressure range (20.2%) 
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FIGURE 12 
POSTPARTUM RETURN OF BLOOD PRESSURE TO BASELINE 
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TABLE 13 
FETAL OUTCOME 
BIRTHWEIGHT OF THE BABIES 
Birth Weight (kgs) No of babies Percentage 
<2 123 27.3% 
2.1-2.5 137 30.5% 
2.6-3 141 31.4% 
>3.1 49 10.8% 
Total 450 100% 
 
 
 
FIGURE 13 
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TABLE 14 
BIRTHWEIGHT ACCORDING TO TYPES OF HYPERTENSION 
Birth 
Weight 
(kgs) 
Gestational 
HT 
Preeclampsia 
Severe 
PE 
Eclampsia 
Chronic 
HT 
Total 
<2 0 
6 
(4.8%) 
78 
(43.8%) 
39 
(60.9%) 
0 
123 
(27.4%) 
2.1-2.5 
17 
(21.8%) 
45 
(36%) 
59 
(33.2%) 
16 
(25%) 
0 
137 
(30.4%) 
2.6-3 
41 
(52.6%) 
56 
(44.8%) 
32 
(18%) 
9 
(14.1%) 
3 
(60%) 
141 
(31.3%) 
>3.1 
20 
(25.6%) 
18 
(14.4%) 
9 
(5%) 
0 
2 
(40%) 
49 
(10.9%) 
Total 78 125 178 64 5 450 
Chi-Square value: 166.2      P value: 0.001 
Statistically significant 
 Most of the babies born to hypertensive mothers weighed between 2.6 to 
3 kgs (31.3%). This was closely followed by babies weighing between 2.1 to 
2.5 kgs (30.4%) which was almost similar to the previous category. Only 10.9% 
of babies weighed more than 3 kgs while 27.4% of babies were below 2 kgs. 
 While in Gestational Hypertension and Mild Preeclampsia, the majority 
of the babies weighed between 2.6 to 3 kgs, in Severe Preeclampsia and 
Eclampsia group, the majority of the babies weighed below 2 kg.  
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FIGURE 14 
BIRTHWEIGHT OF BABIES ACCORDING TO TYPES OF 
HYPERTENSION 
 
 
 
0
10
20
30
40
50
60
70
80
Gestational HT Preeclampsia Severe PE Eclampsia
<2 2.1-2.5 2.6-3
  
72 
 
TABLE 15 
FETAL COMPLICATIONS 
Fetal Complications 
Number of 
babies 
Percentage 
Birth asphyxia 17 3.8% 
IUGR 72 16% 
Neonatal Death 16 3.5% 
Pre maturity 139 30.9% 
Still Birth 2 0.4% 
IUD 25 5.5% 
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TABLE 16 
FETAL COMPLICATIONS IN HYPERTENSION TYPES 
Fetal 
Complications 
Gestational 
HT 
Preeclampsia 
Severe 
PE 
Eclampsia 
Chronic 
HT 
Total 
Neonatal Death 0 2 9 5 0 
16 
(3.5%) 
Stillbirth 0 0 2 0 0 
2 
(0.4%) 
Prematurity 6 19 93 20 1 
139 
(30.9%) 
IUD 0 0 21 4 0 
25 
(5.5%) 
IUGR 4 22 37 9 0 
72 
(16%) 
Birth asphyxia 0 3 9 5 0 
17 
(3.8%) 
Total 10 46 171 43 1 271 
 
 Out of all the babies born to mothers with hypertension, 231 babies were 
born without any complication (51.3%). 219 babies developed some form of 
complication of which few babies had overlapping (more than one) 
complication.  
 In total, there were 25 Intrauterine Deaths (5.5%) of which 21 IUDs 
occurred in the Severe Preeclampsia group and 4 IUDs occurred in Eclamptic 
women. There were only 2 stillbirths in the study group (0.4%) and both of 
these occurred in the Severe Preeclampsia group.  
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 Totally there were 16 Early Neonatal deaths (3.5%) of which the majority 
were in the Severe Preeclampsia group (9 deaths) and the next common in the 
Eclampsia group (5 deaths). 
 The most common complication however is Prematurity with an 
incidence of 30.9% and the next common complication was IUGR with an 
incidence of 16%. Birth Asphyxia occurred in 3.8% of babies.    
 
 
FIGURE 16 
FETAL COMPLICATIONS 
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TABLE 17 
FETAL MORTALITY IN HYPERTENSION TYPES 
Fetal 
outcome 
Gestational 
HT 
Preeclampsia 
Severe 
PE  
Eclampsia 
Chronic 
HT 
Total 
Perinatal 
Deaths 
0 
2 
(1.6%) 
11 
(6.1%)  
5 
(7.8%) 
0 
18 
(4%) 
IUD 0 0 
21 
(11.8%)  
4 
(6.3%) 
0 
25 
(5.5%) 
Live births 
78 
(100%) 
123 
(98.4%) 
146 
(82.1%)  
55 
(85.9%) 
5 
(100%) 
407 
(90.5%) 
Total 78 125 178 
 
64 5 450 
 
Chi-Square value: 40.52       P value: 0.001 
Statistically significant 
 Of all the results of hypertensive pregnancies, 90.5% were successful 
resulting in live births. IUDs constituted about 5.5% while perinatal deaths 
made up 4% of all hypertensive pregnancies.  
 Of all IUDs, the majority occurred in Severe Preeclampsia (21 IUDs) 
while 4 deaths occurred in Eclampsia. Majority of perinatal deaths also occurred 
in Severe Preeclampsia (11 deaths) with Eclampsia being the next common (5 
deaths).  
 There was no mortality in Gestational hypertension, Mild Preeclampsia 
and Chronic Hypertension groups.  
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FIGURE 17 
FETAL MORTALITY IN HYPERTENSION TYPES 
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DISCUSSION 
 450 antenatal women with hypertensive disorder of pregnancy were 
studied after taking into consideration the inclusion and exclusion criteria for a 
period of one year. These women were studied for their demographic characters 
such as age, parity and socioeconomic class. Gestational age at delivery, mode 
of termination, maternal complications and fetal outcomes were also studied. 
 
INCIDENCE AND DISTRIBUTION OF HYPERTENSION IN 
PREGNANCIES  
 The exact incidence of hypertensive disorders complicating pregnancy 
could not be determined by the study since the exclusion criteria of the study 
ruled out multiple pregnancies, pregnancies with other comorbidities such as 
diabetes mellitus, renal disorders and so on.  
 Of the 450 women in our study, the most common hypertension type was 
Severe Preeclampsia with an incidence of 39.6% while the next common was 
Mild Preeclampsia with an incidence of 27.8%. Similar findings were reported 
by Seyom et al45 in whose study Severe Preeclampsia was the most common 
with an incidence of 35.5%. However this was followed by Eclampsia (19%) 
and then by Mild Preeclampsia (14.9%). The proportion of Eclampsia in our 
study is 14.2%. 
 The proportion of Chronic Hypertension was noted to be around 4% in 
the Indian study by Yadav and Saxena46. However in our study, chronic 
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hypertension constituted only 1.1% of all cases. This discrepancy might be due 
to the fact that the presence of other comorbidities has been already ruled out 
and hence the figure of women with pure hypertension alone dips.   
AGE DISTRIBUTION 
 The maximum incidence of hypertension during pregnancy in our study 
was noted in the age group between 21 to 25 years (51.8%) which was followed 
by the age group 26-30 years (22.9%). This only goes to prove the point that 
child bearing age is earlier in our developing country when compared with 
developed nations. Almost analogous findings were reported by Seyom et al45 
with 82.6% of hypertensive mothers falling within the broad age group of 18-34 
years. Also, Aabidha et al reported an incidence of 46.23% in the age group 21-
25 yrs and 23.65% in the age group 26-30 yrs47. 
PARITY 
 It has been traditionally said that Preeclampsia is a disease of primiparity. 
Conforming to the same, primigravida constituted 60.7% of all hypertensive 
mothers in our study. The next majority were the second gravida making up 
27.3% while higher parity make up the rest (12%). These results are similar to 
those noted by Aabidha et al in a study done in a secondary care center in 
TamilNadu where primigravida constituted 61.2% and second gravida made up 
21.5%47. Also the study by Bhattacharya49 showed that primigravida constituted 
65.6% of total cases. 
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SOCIOECONOMIC STATUS 
 Our study shows 81.6% of women belonging to Socioeconomic class V 
and the rest (18.4%) belonging to Socioeconomic class V. This data goes to 
prove the type of population the tertiary care center caters to. 
GESTATIONAL AGE AT DELIVERY 
 In both Gestational hypertension and mild preeclampsia, majority of 
mothers delivered at term (>37 weeks). But in both severe preeclampsia and AP 
Eclampsia, most women delivered as late preterm (between 35 and 37 weeks).  
MODE OF DELIVERY 
 In our study, LSCS was the common mode of termination of the 
pregnancy (in 50% of cases) closely followed by Labour Natural (in 39.3%). 
Assisted delivery in the form of forceps, vacuum etc was resorted to in 4.4% of 
cases. This correlates well with the Indian study conducted by Meshram et al48 
where abdominal route (including both LSCS and hysterotomy) was the 
common method of terminating hypertensive pregnancies with a slightly higher 
incidence than in our study (65.6%). Vaginal delivery constituted about 34.4% 
in their study while this was slightly higher (39.3%) in our study.   
BP RETURN TO BASELINE 
 Majority of patients have become normotensive within 2 days postpartum 
(41.1%) while 20.7% had their BP returned to baseline within 3-13 days and 
20.2% became normotensive after 2 weeks.  
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MATERNAL COMPLICATIONS 
 Maternal complications occurred in 21.6% of cases in our study as 
opposed to 18% in the study by Seyom et al45. The most common maternal 
complication noted in our study was that of Placental abruption (11.3%) 
followed by PPH (6%). This is more or less alike to the South Indian study 
conducted by Aabidha et al47 where APH constituted 13.97% and PPH 
constituted 10.75% of pregnancies. Study by Seyom et al45 reported a 7.4% 
incidence of PPH in pregnancy induced hypertension. Excepting preterm 
labour, Abruptio Placenta was the most common complication (19.04%) in the 
study by Bangal et al50 also.  
 The incidence of HELLP syndrome in our study was 1.8% as opposed to 
the incidence of 2.2% in the study by Yucesoy et al51. The incidence of 
Retinopathy was 0.2% as opposed to incidence of 1.4% in the study by Nankali 
et al52. 
 Maternal mortality was noted in 0.6% in our study as opposed to 1.2% in 
the study by Ahmed et al53.  
FETAL COMPLICATIONS 
 Prematurity is the most common complication occurring in 30.9% of 
deliveries. Similar findings were reported by Bangal et al50 where incidence of 
prematurity were 17.99%, 47.62% and 52.63% in Mild Preeclampsia, Severe 
Preeclampsia and Eclampsia respectively. The next common complication was 
IUGR (16%) which is also in accordance with the study by Bangal et al50 
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wherein the incidence were 7.69%, 26.19% and 31.58% respectively in the 
above categories. 
 Our study revealed 42.2%, 30.4% and 27.4% of babies with birth weights 
>2.5 kg, between 2 and 2.5 kg and <2 kg respectively. Similar findings were 
reported by Ahmed et al53 where the percentages in the respective classes were 
45.2%, 26% and 28.8% respectively.  
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CONCLUSION 
 
 From the above demographic and other data presented, it becomes 
evident that Pregnancy Induced Hypertension is one of the major causes of 
admissions to antenatal wards apart from being a significant contribution 
towards maternal morbidity, mortality and complications. Complications can 
affect all maternal systems including Central nervous system, renal system and 
hematological systems. Apart from these, the fetus also faces the brunt of insult. 
Fetal complications include prematurity, low birth weight, still births, 
intrauterine deaths and intrauterine growth restrictions. However such vast 
complications can be prevented by simple blood pressure monitoring and proper 
antenatal mother followup. Regular antenatal monitoring along with intrapartum 
fetal surveillance can help us in deciding about the mode of termination of the 
pregnancy. In addition to the timely diagnosis of the various complications, 
prompt referral to higher centers is also essential for expert opinion and other 
specialty opinion. Cases which were promptly followed up and managed on a 
regular basis were found to be associated with lower rates of morbidity.  
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LIMITATIONS 
 
 The major limitation of the study is its exclusion criteria. Since the 
exclusion criteria excluded other co-morbidities such as diabetes mellitus, renal 
disorders and so on, the exact incidence and figures of Pregnancy Induced 
Hypertension could not be determined. However since the other high risk 
conditions have been ruled out, the advantage is that the study showed the 
potentiality of complications arising out of pure hypertensive etiology alone.   
 The other limitation of the study is that of the few selected patients who 
were managed on an outpatient basis, a small number were lost in follow up 
reducing an insignificant number of patients in the process.  
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ABBREVIATIONS 
GHT – Gestational Hypertension 
AP Eclampsia – Antepartum Eclampsia 
IP Eclampsia – Intrapartum Eclampsia 
PP Eclampsia – Postpartum Eclampsia 
Severe PE – Severe Preeclampsia 
VEGF – Vascular Endothelial Growth Factor 
PIGF – Placental Growth Factor 
HELLP – Hemolysis, Low platelets, Low platelets 
ARF – Acute Renal Failure 
NST – Non Stress Test 
CTG – Cardiotocography 
LN – Labour Natural 
LSCS – Lower Section Caesarean Section 
LDH – Lactate Dehydrogenase 
AST – Aspartate Transaminase 
ALT – Alanine Transaminase 
PT – Prothrombin Time 
DIC – Disseminated Intravascular Coagulation 
 
 
 
  
 
 
PROFORMA 
Study No :      Hospital No. : 
Name :      Occupation  : 
Age  : 
Address : 
 
SOCIO- ECONOMIC STATUS: 
1. CHIEF COMPLAINTS                                         
2. HISTORY OF PRESENTING COMPLAINTS  
H/o months of amenorrhea 
C/o pain abdomen      yes/no 
C/o leaking/bleeding PV 
C/o headache/blurring of vision/pedal edema 
C/o oliguria / epigastric pain 
3. OBSTETRIC HISTORY  
Married life    
Consanguinity   
  
 
 
Obstetric score: Gravida 
                           Para 
                           Living 
                           Abortion 
                           Dead 
Booked/ Unbooked 
Details of each pregnancy: 
No of 
pregnancies 
Period of 
gestation 
Associated 
complications 
Outcome 
NVD/LSCS 
Baby details 
     
 
 Present pregnancy: booked at 
 Trimester history: 
 I trimester:  H/O excessive vomiting/fever/UTI 
                         Folic acid supplementation 
                     Dating scan 
II trimester:  Quickening felt at 
  
 
 
                      Anomaly scan 
                      C/O headache/blurring of vision/pedal edema                         
III trimester: Perceiving fetal movement                 
                      C/O headache/pedal edema/blurring of vision   
4. MENSTRUAL HISTORY 
 Age of Menarche: 
 Flow: 
 Clots: 
 Dysmenorrhoea:  
 LMP:   Wks.   Days 
 EDD:   Wks.   Days 
5. PAST HISTORY 
TB / Bronchial asthma/ RHD/Blood transfusion / Any operations 
6. FAMILY HISTORY  
TB / Bronchial Asthma / Diabetes mellitus / Hypertension / Any cancer / 
Bleeding disorders / Thyroid disorders  
 
  
 
 
7. PERSONAL HISTORY 
Diet     :  
Appetite   :  
Bowels   : 
Micturition    :  
Sleep    : 
Excessive intake of coffee : 
8. EXAMINATION OF PATIENT: 
    On examination  
1. Height in cms               : 
2.  Pre pregnant Weight : 
Present weight : 
 Weight gain  : 
BMI    : 
3. Temperature in degree 
4. BP in mm of Hg 
5. Respiratory rate per minute 
  
 
 
6. Pulse rate 
7. Pallor 
8. Edema 
9. Icterus  
 Pre pregnant Weight : 
Present weight  : 
 Weight gain   : 
BMI     : 
Systemic examination 
a. CVS 
 b. RS  
 c. Per abdomen : 
Inspection:  abdomen-normal/over distended 
Striae gravidarum  :  
       Linea nigra   : 
Dilated veins/sinuses : 
           Palpation:  Fundal height: 
  
 
 
                  Fundal grip   :                                    
                  Lateral grip    :                                      
                  Pelvic grip                        :                                     
                  Liquor: adequate/scanty 
Auscultation: FHS (/min) 
EFW 
Per vagina: cervix dilatation: 
Length  : 
Effacement  :  
Position  : 
Consistency  : 
Vertex station   : 
Membranes    : 
Pelvis: adequate/not: 
DIAGNOSIS: 
Investigations  
Hb 
  
 
 
RBS 
PCV  
Blood group  
Urine routine: albumin/ Sugar 
BT 
CT 
HIV  
HBsAg  
VDRL 
PIH PROFILE:   
Blood urea 
Serum Creatinine 
Serum Uric acid 
 LFT 
Platelet count: 
Lipid profile 
 
  
 
 
Fundoscopy  
USG  
Electrocardiogram 
Echocardiogram 
Pregnancy outcome: 
• Gestational age at delivery 
• Vaginal delivery: assisted/ spontaneous 
• Caesarean section 
• Maternal complications 
Perinatal outcome:  
• Live/Still birth/IUD 
• Male/female 
• Birth weight 
• Fetal distress during labor 
• APGAR score less than 7 
• NICU admission 
• Neonatal Deaths 
• Neonatal complications 
 
  
 
 
PATIENT INFORMATION SHEET 
Place of Study: Chengalpattu Medical College Hospital 
Name of the Investigator: Dr. Suganthi P 
Name of the Participant:  Age:   Hospital No: 
Title: “CLINICAL STUDY ON DEMOGRAPHIC PROFILE, 
MATERNAL AND PERINATAL OUTCOME IN PREGNANT WOMEN 
WITH HYPERTENSIVE DISORDER”   
➢ You are invited to take part in this study. The information in the 
document is meant to help you decide whether or not to take part. Please 
feel free to ask if you have any queries or concerns. 
Purpose of the research: 
➢ We are conducting a study on “Demographic profile, Maternal and 
perinatal outcome in pregnant women with hypertensive disorder” 
➢ The purpose of the study is to find the incidence of hypertensive disorder 
and fetomaternal morbidity and mortality among these groups. 
➢ The privacy of the patient in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from 
the research, no personally identifiable information will be shared. 
  
 
 
➢ Taking part in the study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time. Your decision will not 
result in any loss of benefits to which you are otherwise entitled 
➢ The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment. 
➢ We have obtained permission from the Institutional Ethical Committee. 
 
Principal investigator 
DR.SUGANTHI.P 
II year MS O & G,  
Department of Obstetrics and Gynaecology 
Chengalpattu Medical College Hospital, 
 Chengalpattu 
 
Place:         
Date:         Signature of patient 
 
 
 
  
 
 

•


•
•





செங்கல்படட்ு அரசு சபொது மருத்துவமனையில் மகப்பபறு மற்றும் 
மகளிர் நல துனறயில் ஆரொய்ெச்ி நனடசபற்றுவருகிை்றது. 
நீங்களும் இந்த ஆரொய்ெச்ியில் பங்பகற்க நொங்கள் 
விரும்பிகிபறொம் .இதைொல் உங்களுக்கு எந்த பொதிப்பும் ஏற்படொது 
எை்பனத சதரிவித்துக் சகொள்கிபறொம். 
முடிவுகனள அல்லது கருத்துகனள சவளியிடும் பபொதுஅல்லது 
ஆரொய்ெச்ியிை் பபொது உங்களது சபயனரபயொ அல்லது 
அனடயொளங்கனளபயொ சவளியிடமொட்படொம் எை்பனதயும் 
சதரிவித்துக்சகொள்கிபறொம். 
இந்த ஆரொய்ெச்ியில் பங்பகற்பது தங்களுனடய விருப்பத்திை் 
பபரில் தொை் இருக்கிறது. பமலும்நீங்கள் எந்த பநரமும் இந்த 
ஆரொய்ெச்ியிலிருந்து  பிை்வொங்கலொம் எை்பனதயும் சதரிவித்துக் 
சகொள்கிபறொம். 
இந்த சிறப்பு பரிபெொதனைகளிை் முடிவுகனள ஆரொய்ெச்ியிை் 
முடிவிை் பபொதுதங்களுக்கு அறிவிப்பபொம் எை்பனதயும் 
சதரிவித்துக் சகொள்கிபறொம். 
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MASTER CHART 
S. NO NAME AGE PARITY 
SE  
CLA
SS 
HT CLASS 
MODE 
OFDELIVERY 
GA AT 
DELIVERY 
MATERNAL 
COMPLICATIONS 
POSTPARTUM 
RETURN TO 
BASELINE 
BIRTH 
WEIGHT 
FETAL 
COMPLICATIONS 
1 Kowsalya Mani 19 Primi V Preeclampsia LSCS 37 weeks   1 day 2.4 kg Prematurity 
2 Manimegalai 24 Primi V Gestational HT 
Assisted 
delivery 
38 weeks   1 day 2.3 kg   
3 Revathy 23 Primi IV Preeclampsia LSCS 38 weeks   1 day 2.3 kg IUGR 
4 Poongavanam 33 G2A1 V 
Severe 
Preeclampsia 
LSCS 39 weeks   2 weeks 3.3 kg   
5 Hemavathy 26 Primi V Preeclampsia LN 39 weeks   1 day 2.7 kg   
6 Surya Banu 20 Primi IV Preeclampsia LN 36 weeks   2 days 2.8 kg Prematurity 
7 Ragini 26 Primi V AP Eclampsia LSCS 38 weeks   2 weeks 2.4 kg   
8 Sujatha 31 Primi IV AP Eclampsia LSCS 33 weeks CVA   10 days 1.5 kg Prematurity 
9 Bhuvaneswari 21 
G3P1L1
A1 
IV Gestational HT LN 39 weeks   1 day 3.1 kg   
10 Seetha 21 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
29 weeks Abruptio placenta   IUD IUD 
11 Abirami 28 Primi V Preeclampsia LSCS 38 weeks Abruptio placenta 2 days 2.9 kg   
12 Sujatha 31 Primi IV Gestational HT LN 40 weeks   2 days 2.7 kg   
13 Nandhini 25 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 39 weeks   10 days 2.4 kg   
14 Amala 22 G2P1L1 IV Preeclampsia LSCS 40 weeks   10 days 2.3 kg   
15 Dhanalakshmi 25 Primi IV AP Eclampsia LN 30 weeks   3 weeks 1.4 kg Prematurity 
16 Janani 27 Primi V 
Severe 
Preeclampsia 
LSCS 39 weeks   1 week 3.2 kg   
17 Ponmari 20 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks Abruptio placenta   2.3 kg 
Prematurity & 
IUGR 
18 Valli 25 G4P3L3 IV 
Severe 
Preeclampsia 
LSCS 32 weeks   1 week 1.4 kg Prematurity 
19 Mahalakshmi 22 Primi V Gestational HT LSCS 40 weeks   2 days 2.8 kg   
20 Anjugam 26 Primi V Gestational HT LSCS 40 weeks   2 days 3.4 kg   
21 Suseela  24 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 37 weeks PPH 2 weeks 2.4 kg Birth asphyxia 
  
 
 
22 Gowthami 25 P1L1 IV Preeclampsia LN 39 weeks   2 days 3.1 kg   
23 Valli 25 P4L4 V Preeclampsia 
Assisted 
delivery 
37 weeks   1 day 2.6 kg Prematurity 
24 Lakshmi 24 G2P1L1 V Gestational HT LN 39 weeks   1 day 2.6 kg   
25 Subha 21 Primi IV 
Severe 
Preeclampsia 
LSCS 39 weeks   10 days 2.7 kg   
26 Vimala 24 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   2 days 1.6 kg 
Prematurity & 
IUGR 
27 Silambarasi 30 Primi V Gestational HT LSCS 38 weeks   1 day 2.4 kg   
28 Kavitha 27 G2P1L1 IV Chronic HT LSCS 37 weeks     2.7 kg   
29 Sangeetha  26 G2P1L1 IV Preeclampsia LSCS 39 weeks   1 day 2.8 kg   
30 Ramya 27 
G4P2L2
A1 
IV 
Severe 
Preeclampsia 
LSCS 35 weeks   2 weeks 1.5 kg 
Prematurity & 
IUGR 
31 Mercy 30 
G5P2L2
A2 
V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
33 weeks Abruptio placenta 3 weeks IUD IUD 
32 Anitha 22 G3A2 V Gestational HT LN 39 weeks   1 day 2.7 kg   
33 Poongodi 32 G2A1 V Preeclampsia LSCS 37 weeks   2 days 2.3 kg 
Prematurity & 
IUGR 
34 Tamilselvi 24 Primi IV Gestational HT LSCS 40 weeks   2 days 3.7 kg   
35 Jothi 33 G2P1L1 V Chronic HT LSCS 39 weeks     3.2 kg   
36 Vasantha 21 Primi IV 
Severe 
Preeclampsia 
LSCS 36 weeks   2 weeks 2.2 kg Prematurity 
37 Anjali  29 
G4P2L1
A1 
V Gestational HT LSCS 39 weeks   2 days 2.3 kg   
38 Ambika 28 Primi IV 
Severe 
Preeclampsia 
LSCS 39 weeks Abruptio placenta 10 days 2.8 kg   
39 Hemavathy 22 Primi IV Preeclampsia LSCS 38 weeks   2 days 2.8 kg   
40 Sudha 30 Primi V 
Severe 
Preeclampsia 
LSCS 32 weeks   1 week 1.6 kg Prematurity 
41 Rekha 26 
G3P1L1
D1 
V Preeclampsia LN 39 weeks   2 days 2.9 kg   
42 
Gnanasoundha
ri 
25 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   2 weeks 2.2 kg Prematurity 
43 Devaki 20 Primi IV Preeclampsia LSCS 40 weeks Abruptio placenta 2 days 2.6 kg   
44 Prema 34 G2P1L1 IV Gestational HT LN 39 weeks   2 days 2.9 kg   
45 Kabhija 34 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 35 weeks   1 week 1.8 kg 
Prematurity & 
IUGR 
46 Saranya 25 Primi V Preeclampsia 
Assisted 
delivery 
36 weeks   2 days 2.2 kg Prematurity 
47 UdhayaPaapa 32 G2P1L1 IV 
Severe 
Preeclampsia 
LSCS 38 weeks   10 days 2.1 kg IUGR 
48 Nandhini 24 
G4P1L1
A2 
V Preeclampsia LSCS 38 weeks   1 week 3.3 kg   
49 Revathy 23 Primi V 
Severe 
Preeclampsia 
LSCS 30 weeks     1.6 kg Prematurity 
50 Parimala 24 Primi V Preeclampsia LN 39 weeks   2 days 2.6 kg   
51 Selvi 26 G2A1 IV 
Severe 
Preeclampsia 
LSCS 39 weeks Abruptio placenta 3 weeks 2.4 kg   
52 
Thiripurasundh
ari 
20 Primi IV Gestational HT LN 39 weeks   2 days 2.6 kg   
53 Leena 37 G2P1L1 IV Preeclampsia LSCS 39 weeks   1 day 2.7 kg   
54 Shobana 27 G2P1L1 V Gestational HT LSCS 38 weeks   2 days 2.7 kg   
55 Ponnamal 26 Primi V AP Eclampsia LSCS 30 weeks   2 weeks 1.4 kg Prematurity 
56 Brindha 21 Primi IV Preeclampsia LN 37 weeks PPH 2 days 2.6 kg Prematurity 
57 Suganthi 26 G2P1L1 IV 
Severe 
Preeclampsia 
LSCS 36 weeks   10 days 1.6 kg 
Prematurity & 
IUGR 
58 Geetha 29 Primi V Gestational HT   38 weeks   2 days 2.5 kg   
59 Ushaselvi 41 Primi V 
Severe 
Preeclampsia 
LN 38 weeks PPH   2.7 kg Birth asphyxia 
60 Geetha 25 G2P1L1 IV 
Severe 
Preeclampsia 
LSCS 30 weeks Abruptio placenta 10 days 1.3 kg Prematurity 
61 Punitha 35 Primi IV Preeclampsia LN 37 weeks   2 days 2.4 kg Prematurity 
62 Geetha 30 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 39 weeks   2 weeks 2.2 kg IUGR 
63 Anuja 26 P1L1 V Preeclampsia LSCS 40 weeks   2 days 2.8 kg   
64 Meenatchi 25 G2P1L1 IV 
Severe 
Preeclampsia 
LN 36 weeks Abruptio placenta 3 weeks 2.2 kg Prematurity 
65 Nandhini 24 P1L1 IV Preeclampsia LN 38 weeks   2 days 3.2 kg   
66 Yamunadevi 26 Primi V Gestational HT LSCS 38 weeks   1 day 2.3 kg   
  
 
 
67 Prabhavathi 27 G2A1 V 
Severe 
Preeclampsia 
LSCS 32 weeks   1 week 1.4 kg Prematurity 
68 Arulvizhi 24 
G4P3L2
D1 
IV Preeclampsia LN 39 weeks   1 day 2.2 kg IUGR 
69 Suseela  32 G2P1L1 V Gestational HT LN 38 weeks   2 days 3.2 kg   
70 Sridevi 30 G4A3 V Preeclampsia LN 40 weeks   1 day 3.2 kg   
71 Durga 24 Primi IV AP Eclampsia 
Spontaneous 
expulsion 
27 weeks CVA   2 weeks IUD IUD 
72 Malathi 22 Primi V 
Severe 
Preeclampsia 
LN 35 weeks PPH 2 weeks 2.1 kg Prematurity 
73 Jothika 24 Primi IV 
Severe 
Preeclampsia 
LSCS 38 weeks     2.9 kg   
74 Banupriya 24 
G5P3L2
A1 
V 
Severe 
Preeclampsia 
LN 39 weeks   10 days 3.3 kg   
75 Suganya 21 P1L1 IV PP Eclampsia LN 35 weeks   2 weeks 1.3 kg Prematurity 
76 Divya 21 P1L1 V PP Eclampsia LSCS 39 weeks   3 weeks 2.9 kg   
77 Vanaja 24 G2P1L1 IV AP Eclampsia LSCS 36 weeks ARF 2 weeks 2.3 kg   
78 Porkodi 26 Primi V AP Eclampsia LSCS 33 weeks CVA   1 week 1.6 kg Prematurity 
79 Sridevi 30 G4A3 V Gestational HT 
Assisted 
delivery 
39 weeks   1 day 3.2 kg   
80 Angujarathi 21 Primi IV 
Severe 
Preeclampsia 
LSCS 39 weeks ARF 3 weeks 2.1 kg IUGR 
81 Priyanka 21 Primi V Preeclampsia 
Assisted 
delivery 
39 weeks   2 days 2.7 kg Birth asphyxia 
82 Vasanthi 22 Primi V AP Eclampsia LSCS 30 weeks Pulmonary edema   1.6 kg Birth asphyxia 
83 Merlin 22 G2P1L1 IV 
Severe 
Preeclampsia 
LN 36 weeks   2 days 2.6 kg Prematurity 
84 Nivedha 20 Primi V 
Severe 
Preeclampsia 
LN 35 weeks   1 week 1.9 kg 
Birth asphyxia  & 
IUGR 
85 Saraswathi 21 Primi V Gestational HT LN 39 weeks   1 day 2.9 kg   
86 Nancy 24 G2P1L1 V Preeclampsia LN 40 weeks   2 days 2.8 kg   
87 Ramya 23 G2A1 IV Preeclampsia LSCS 40 weeks Abruptio placenta 10 days 2.6 kg   
88 Priyanka 25 P1L1 V Preeclampsia LSCS 39 weeks   2 days 2.6 kg   
89 Sherena Banu 25 G3P2L2 IV Gestational HT LSCS 40 weeks   2 days 2.8 kg   
90 Jayalakshmi 25 G2P1L1 V AP Eclampsia LSCS 37 weeks   1 week 2.7 kg   
91 Malathi 21 Primi V 
Severe 
Preeclampsia 
LN 39 weeks   10 days 2.1 kg IUGR 
92 Bhuvaneswari 26 Primi V Preeclampsia LSCS 38 weeks PPH 2 days 2.3 kg Prematurity 
93 Vijayalakshmi 23 Primi IV Gestational HT LN 40 weeks   1 week 2.7 kg   
94 Jeevitha 26 Primi IV Gestational HT LN 40 weeks   2 days 2.7 kg   
95 Divya 21 Primi V AP Eclampsia LSCS 40 weeks   2 weeks 2.3 kg   
96 Nandhini 23 G2P1L1 IV 
Severe 
Preeclampsia 
LSCS 33 weeks Abruptio placenta 1 week 1.4 kg Prematurity 
97 Rasathi 22 Primi V Preeclampsia LSCS 39 weeks   2 days 2.8 kg   
98 
Shanthalakshm
i 
24 Primi V Preeclampsia LN 40 weeks   1 day 2.7 kg   
99 Jeeva  26 G2P1L1 IV Gestational HT LSCS 39 weeks   1 day 2.6 kg   
100 Kalaivani 26 Primi V AP Eclampsia LSCS 38 weeks Abruptio placenta 1 week 2.4 kg   
101 Sasikala 22 Primi V 
Severe 
Preeclampsia 
LN 38 weeks   10 days 2.8 kg   
102 Shalini 25 Primi IV 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
30 weeks Abruptio placenta 2 weeks IUD IUD 
103 Sangeetha  19 Primi V Preeclampsia LN 39 weeks   1 day 3.5 kg   
104 Gowthami 22 G2P1L1 V Gestational HT LN 39 weeks   1 day 2.9 kg   
105 Karpagavalli 23 Primi V Preeclampsia LSCS 40 weeks   2 days 2.6 kg   
106 Revathy 19 Primi IV Preeclampsia LN 39 weeks   2 days 2.2 kg IUGR 
107 Kasthuri 21 Primi V Gestational HT 
Assisted 
delivery 
37 weeks   1 day 2.3 kg Prematurity 
108 Ammu 20 Primi V 
Severe 
Preeclampsia 
LN 37 weeks   3 weeks 1.8 kg 
Prematurity & 
IUGR 
109 Fathima 19 Primi V 
Severe 
Preeclampsia 
LSCS 39 weeks   3 weeks 2.2 kg IUGR 
110 Revathy 27 Primi IV Preeclampsia LN 38 weeks   1 day 3.1 kg   
111 Muthulakshmi 23 Primi V 
Severe 
Preeclampsia 
LN 35 weeks   1 day 1.5 kg 
Prematurity & 
IUGR 
  
 
 
112 Roobini 20 Primi V 
Severe 
Preeclampsia 
LSCS 34 weeks 
Abruptio placenta, 
HELLP & DIC 
3 weeks 1.7 kg Prematurity 
113 Sumathy 24 Primi V Preeclampsia LSCS 39 weeks   3 weeks 2.9 kg   
114 Kavitha 23 G2P1L1 IV PP Eclampsia LN 35 weeks   2 weeks 1.5 kg Prematurity 
115 Sindhu 21 Primi V Preeclampsia LN 38 weeks   1 day 2.6 kg Prematurity 
116 Jayasree 21 G2P1L1 V Gestational HT LSCS 38 weeks   1 day 3.4 kg   
117 Karpagam 27 Primi V Gestational HT LN 38 weeks   2 days 2.6 kg   
118 Mohanapriya 25 Primi IV 
Severe 
Preeclampsia 
LN 35 weeks PPH 1 week 1.8 kg 
Prematurity & 
IUGR 
119 Vanaja 24 G2P1L1 V AP Eclampsia 
Spontaneous 
expulsion 
26 weeks   10 days IUD IUD 
120 Sumathy 24 Primi V 
Severe 
Preeclampsia 
LN 40 weeks   2 weeks 2.4 kg   
121 Chitra 32 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 39 weeks     3.4 kg   
122 Divya 24 Primi IV Preeclampsia LSCS 39 weeks   1 day 2.3 kg IUGR 
123 Panchali 28 G2P1L1 V Preeclampsia LN 40 weeks   1 day 2.7 kg   
124 Sowmya 25 Primi V Preeclampsia LSCS 40 weeks   10 days 2.6 kg   
125 Jayanthi  26 Primi V AP Eclampsia LSCS 30 weeks HELLP 3 weeks 1.7 kg Prematurity 
126 Anjali  25 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   1 week 2.2 kg Prematurity 
127 Saranya 23 Primi IV 
Severe 
Preeclampsia 
LN 38 weeks   1 week 2.7 kg   
128 Kalaiselvi 26 Primi V 
Severe 
Preeclampsia 
LN 35 weeks Abruptio placenta 10 days 1.6 kg 
IUGR & Neonatal 
death 
129 Blessy 27 Primi V 
Severe 
Preeclampsia 
LSCS 34 weeks Abruptio placenta 3 weeks 1.8 kg Stillbirth 
130 Mohanapriya 26 G2P1L1 V Preeclampsia LN 39 weeks   1 day 2.9 kg   
131 Dilshandh 25 G2P1D1 V Preeclampsia LSCS 38 weeks   2 days 3.4 kg   
132 Sushmitha  23 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
27 weeks   3 weeks IUD IUD 
133 Sundhari 25 Primi IV 
Severe 
Preeclampsia 
LN 36 weeks   10 days 2.4 kg   
134 Sarasu 23 Primi V Preeclampsia LSCS 38 weeks   1 day 2.3 kg   
135 
Dhanakoteesw
ari 
26 Primi V Preeclampsia LSCS 39 weeks Abruptio placenta 2 days 2.3 kg   
136 Parvarthi 27 G2A1 V Preeclampsia LN 38 weeks   2 days 1.7 kg IUGR 
137 Radha 23 G3A1 IV 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
36 weeks   10 days IUD IUD 
138 Vasuki 23 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   1 week 1.7 kg 
Prematurity & 
IUGR 
139 Manjula  20 P1L1 V PP Eclampsia LSCS 39 weeks CVA   2 weeks 2.3 kg   
140 Selvi 24 Primi IV Preeclampsia LN 37 weeks   2 days 2.4 kg Prematurity 
141 Jayalakshmi 29 G3P2L2 IV 
Severe 
Preeclampsia 
LN 32 weeks Abruptio placenta 10 days 1.3 kg Prematurity 
142 Ammulu 25 Primi V Preeclampsia LN 38 weeks   1 day 2.8 kg   
143 Priya  27 P2L2A1 IV PP Eclampsia LSCS 36 weeks   3 weeks 2.8 kg   
144 Shanmugavalli 31 G3P2L2 V 
Severe 
Preeclampsia 
LN 38 weeks PPH 3 weeks 2.7 kg Birth asphyxia 
145 Karuthammal 23 Primi V Preeclampsia 
Assisted 
delivery 
39 weeks   2 days 2.9 kg   
146 Sheela  24 Primi IV AP Eclampsia LN 37 weeks PPH 3 weeks 1.7 kg 
Birth asphyxia  & 
IUGR 
147 Kanniyammal 28 Primi V 
Severe 
Preeclampsia 
LSCS 37 weeks   1 week 2.3 kg Prematurity 
148 Muniyammal 21 Primi V Gestational HT LN 39 weeks PPH 10 days 2.8 kg   
149 Sathyavathi 21 Primi IV 
Severe 
Preeclampsia 
LN 38 weeks ARF 10 days 2.2 kg IUGR 
150 Asha 22 G3P2L2 V 
Severe 
Preeclampsia 
Spontaneous 
expulsion  
35 weeks   2 weeks IUD IUD 
151 Rajeswari 30 Primi IV Preeclampsia LN 40 weeks   1 day 2.4 kg   
152 Adhilakshmi 27 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
26 weeks Abruptio placenta 3 weeks IUD IUD 
153 Uma 21 Primi V Preeclampsia LN 39 weeks   10 days 3.3 kg   
154 Geetha 28 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks   2 days 1.8 kg 
Prematurity & 
IUGR 
  
 
 
155 Nithya 28 Primi IV 
Severe 
Preeclampsia 
LSCS 35 weeks 
Abruptio placenta, 
HELLP, DIC & 
Maternal Death 
  2.1 kg Prematurity 
156 Lavanya 23 Primi V Gestational HT LSCS 39 weeks   2 days 2.4 kg IUGR 
157 Kala 24 Primi V Preeclampsia LN 39 weeks   1 day 2.7 kg   
158 LoorthuMary 23 Primi V 
Severe 
Preeclampsia 
LN 34 weeks Abruptio placenta 3 weeks 2.3 kg Prematurity 
159 Nirmala 28 Primi IV 
Severe 
Preeclampsia 
LN 37 weeks   10 days 2.2 kg Prematurity 
160 Maheswari 28 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 37 weeks   1 week 2.8 kg   
161 Renuka 21 Primi V AP Eclampsia LSCS 32 weeks ARF 3 weeks 1.25 kg Prematurity 
162 Sumathy 34 G3A2 V Chronic HT LSCS 36 weeks     2.6 kg Prematurity 
163 
Dhanabooshan
am 
21 Primi V Preeclampsia 
Assisted 
delivery 
40 weeks   1 day 2.9 kg   
164 Sangeetha  21 Primi IV Preeclampsia LN 40 weeks   1 day 2.6 kg   
165 Pushpa 24 G2P1L1 V 
Severe 
Preeclampsia 
LN 33 weeks Abruptio placenta 2 weeks 1.6 kg Prematurity 
166 Saranya 25 Primi V 
Severe 
Preeclampsia 
LSCS 39 weeks Abruptio placenta 3 weeks 2.6 kg   
167 Yasmin 26 Primi V Preeclampsia LN 39 weeks   1 day 2.2 kg IUGR 
168 Soundharya 23 Primi IV 
Severe 
Preeclampsia 
LSCS 35 weeks   1 week 1.6 kg 
Prematurity & 
IUGR 
169 Revathy 26 G2P1L1 V Preeclampsia LSCS 38 weeks   2 days 2.3 kg IUGR 
170 Amala 23 G2P1D1 IV Gestational HT 
Assisted 
delivery 
36 weeks   2 days 2.2 kg 
Prematurity & 
IUGR 
171 Rajalakshmi 27 G3P2L2 V Preeclampsia LN 39 weeks PPH 1 day 2.7 kg   
172 Thilakavathy 24 
G3P1L1
A1 
IV 
Severe 
Preeclampsia 
LN 34 weeks   10 days 1.7 kg Prematurity 
173 Balamani 36 G2P1L1 V Preeclampsia LSCS 39 weeks   2 weeks 3.4 kg   
174 Dharani 27 Primi IV 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
27 weeks   10 days IUD IUD 
175 Yuvarani 20 Primi IV Preeclampsia LN 38 weeks   1 day 2.8 kg   
176 Saraswathy 33 G2P1L1 IV 
Severe 
Preeclampsia 
LN 35 weeks PPH 2 weeks 2.3 kg Prematurity 
177 Priya 26 G2A1 IV Preeclampsia LN 40 weeks   1 day 3.4 kg   
178 Sivaranjini 21 Primi V Preeclampsia LN 40 weeks PPH 10 days 2.9 kg   
179 Alfonsa 19 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   1 week 1.9 kg 
Prematurity & 
IUGR 
180 Kanchana 24 Primi V AP Eclampsia LN 33 weeks   3 weeks 1.4 kg Prematurity 
181 Prema 19 Primi IV Gestational HT LSCS 40 weeks   1 day 3.6 kg   
182 Lalitha 23 Primi V Gestational HT LN 38 weeks   2 days 2.4 kg   
183 Prameela 27 Primi IV Gestational HT 
Assisted 
delivery 
38 weeks   2 days 2.3 kg   
184 Nandhini 20 Primi V 
Severe 
Preeclampsia 
LSCS 33 weeks 
Abruptio placenta, 
HELLP & DIC 
  2.2 kg 
Birth asphyxia & 
Prematurity 
185 Sofiya 21 Primi V Preeclampsia LSCS 39 weeks   1 day 2.4 kg   
186 Usha  25 Primi IV 
Severe 
Preeclampsia 
LSCS 39 weeks   3 weeks 2.7 kg   
187 Banupriya 23 Primi V 
Severe 
Preeclampsia 
LN 39 weeks   10 days 2.9 kg   
188 Bhavani 21 Primi IV 
Severe 
Preeclampsia 
LSCS 36 weeks   1 week 1.7 kg 
IUGR & Neonatal 
death 
189 Shalini 29 G2P1L1 V Preeclampsia LSCS 38 weeks   1 day 1.7 kg 
Prematurity & 
IUGR 
190 Divyabharathi 24 Primi V 
Severe 
Preeclampsia 
LN 35 weeks   2 weeks 1.8 kg 
Prematurity & 
IUGR 
191 Revathy 24 G2P1L1 IV 
Severe 
Preeclampsia 
LN 38 weeks Abruptio placenta 3 weeks 2.1 kg IUGR 
192 Rajapriya 26 Primi V 
Severe 
Preeclampsia 
LN 35 weeks   10 days 2.3 kg   
193 Vasanthi 25 P1L1 V Preeclampsia LSCS 39 weeks   2 days 2.1 kg IUGR 
194 Geethanjali 24 Primi V 
Severe 
Preeclampsia 
LSCS 37 weeks   1 week 2.3 kg Prematurity 
195 Geetha 19 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
27 weeks Abruptio placenta 3 weeks IUD IUD 
196 Keerthi 33 G2P1L1 IV 
Severe 
Preeclampsia 
LSCS 37 weeks Abruptio placenta   2.2 kg Prematurity 
197 Tamilselvi 33 G3P2L2 V Chronic HT LN 38 weeks     2.9 kg   
  
 
 
198 Kaveri 20 Primi V Preeclampsia LN 39 weeks   2 days 2.2 kg IUGR 
199 Lavanya 23 G2P1L1 IV Gestational HT LSCS 38 weeks   2 days 2.7 kg   
200 Sasikala 26 G2P1L1 V 
Severe 
Preeclampsia 
LN 32 weeks   1 week 1.5 kg Prematurity 
201 Amudha 27 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 38 weeks   2 days 2.6 kg   
202 Srimathi 21 Primi IV AP Eclampsia LSCS 35 weeks 
CVA & Maternal 
death 
  1.4 kg Prematurity 
203 Prameela 22 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks   1 week 1.8 kg 
Prematurity & 
IUGR 
204 
Alamelumanga
i 
23 Primi IV Preeclampsia 
Assisted 
delivery 
38 weeks   10 days 2.6 kg   
205 Vimala 27 
G3P1L1
A1 
IV Preeclampsia LN 40 weeks   1 day 2.9 kg   
206 Kalaiarasi 22 Primi IV Gestational HT LSCS 39 weeks   1 day 2.8 kg   
207 Lakshmi 25 Primi V Preeclampsia LN 40 weeks   1 day 3.2 kg   
208 Usha 29 G2P1L1 V Preeclampsia LSCS 38 weeks Abruptio placenta 2 days 1.6 kg 
IUGR & Neonatal 
death 
209 Suvalakshmi 25 Primi V Preeclampsia LN 38 weeks   1 day 2.2 kg IUGR 
210 Deepa 24 Primi IV 
Severe 
Preeclampsia 
LSCS 32 weeks   3 weeks 1.7 kg Prematurity 
211 Rajeswari 24 Primi V 
Severe 
Preeclampsia 
LN 37 weeks   1 week 3.2 kg   
212 Rekha 26 G3P2L2 V 
Severe 
Preeclampsia 
LSCS 27 weeks   2 weeks 1.3 kg Prematurity 
213 Shakila 27 Primi IV 
Severe 
Preeclampsia 
LSCS 37 weeks   10 days 2.3 kg IUGR 
214 Bavani 24 Primi V Preeclampsia LN 39 weeks   1 week 2.8 kg   
215 Dilshandh 21 Primi V 
Severe 
Preeclampsia 
LN 37 weeks   10 days 2.1 kg 
Prematurity & 
IUGR 
216 Shakthi 21 Primi IV 
Severe 
Preeclampsia 
LSCS 33 weeks   2 weeks 1.5 kg Prematurity 
217 Vanitha 21 Primi V 
Severe 
Preeclampsia 
LN 40 weeks   10 days 2.7 kg   
218 Priyanka 27 
G3P1L1
A1 
V 
Severe 
Preeclampsia 
LSCS 36 weeks   3 weeks 2.3 kg Prematurity 
219 Hayathi 21 Primi IV 
Severe 
Preeclampsia 
LN 36 weeks   10 days 2.8 kg Prematurity 
220 Sathyavani 25 Primi V Gestational HT 
Assisted 
delivery 
39 weeks   2 days 2.3 kg IUGR 
221 Selvi 25 Primi V Preeclampsia LN 39 weeks PPH 2 days 3.3 kg Birth asphyxia 
222 Maria 24 Primi IV Preeclampsia LN 38 weeks   1 day 2.7 kg   
223 Parimala 18 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
26 weeks   2 weeks IUD IUD 
224 Ishwari 23 Primi V Gestational HT LN 38 weeks   10 days 2.9 kg   
225 Saranya 25 Primi V 
Severe 
Preeclampsia 
LSCS 34 weeks Abruptio placenta 10 days 2.2 kg Prematurity 
226 Bavani 20 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   1 week 1.6 kg 
Prematurity & 
IUGR 
227 Banupriya 26 G2P1L1 V Preeclampsia LN 39 weeks   3 weeks 2.4 kg   
228 Sathya 22 Primi V 
Severe 
Preeclampsia 
LN 37 weeks PPH 1 week 2.2 kg Birth asphyxia 
229 Kanniyammal 21 Primi V 
Severe 
Preeclampsia 
LSCS 39 weeks   3 weeks 3.5 kg   
230 Shobana 22 Primi V Gestational HT LSCS 39 weeks   2 days 3.2 kg   
231 Tamilselvi 19 Primi V 
Severe 
Preeclampsia 
LSCS 34 weeks   10 days 1.7 kg Prematurity 
232 Sathya 26 Primi V Preeclampsia LN 36 weeks   1 day 1.8 kg 
Prematurity, 
IUGR & Neonatal 
Death 
233 Pavithra 19 Primi V AP Eclampsia LSCS 36 weeks   3 weeks 2.2 kg IUGR 
234 Suganya 23 Primi V 
Severe 
Preeclampsia 
LN 36 weeks   10 days 2.3 kg Prematurity 
235 Monisha 24 Primi V 
Severe 
Preeclampsia 
LSCS 38 weeks Abruptio placenta 10 days 2.3 kg   
236 Ramya 20 Primi V Preeclampsia LSCS 38 weeks   1 day 2.8 kg   
237 Hemavathy 26 Primi V 
Severe 
Preeclampsia 
LN 27 weeks   10 days 1.4 kg Prematurity 
238 Kavitha 24 G2A1 V 
Severe 
Preeclampsia 
LSCS 36 weeks   3 weeks 2.4 kg   
239 Rajeswari 22 Primi V Preeclampsia LN 39 weeks   1 day 3.1 kg   
240 Sathyavani 27 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks   1 week 2.3 kg   
241 Saranya 28 Primi V Preeclampsia LN 36 weeks   2 days 2.2 kg Prematurity 
  
 
 
242 Nithya 26 
G4P1L1
A2 
V 
Severe 
Preeclampsia 
LSCS 34 weeks    3 weeks 1.5 kg Prematurity 
243 Radha 28 G2P1L1 V Preeclampsia LN 39 weeks   2 days 2.2 kg   
244 Manjula  28 
G3P1L1
A1 
V Gestational HT LN 40 weeks   2 days 2.3 kg IUGR 
245 Selvi 29 G3P2L2 V 
Severe 
Preeclampsia 
LN 39 weeks   1 week 2.9 kg   
246 
Chamundeesw
aari 
19 Primi V 
Severe 
Preeclampsia 
LN 26 weeks   10 days 1.3 kg 
Prematurity & 
Neonatal death 
247 Poosanam 23 Primi V AP Eclampsia LSCS 37 weeks CVA   10 days 2.3 kg Birth asphyxia 
248 Srisha 20 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks 
Abruptio placenta, 
HELLP & DIC 
  2.4 kg Prematurity 
249 Meena  23 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 33 weeks Pulmonary edema   1.5 kg 
Prematurity, 
IUGR & Neonatal 
Death 
250 Suganthi 22 Primi V 
Severe 
Preeclampsia 
LN 37 weeks   2 weeks 2.2 kg 
Prematurity & 
IUGR 
251 Mangala 25 Primi V Gestational HT LSCS 40 weeks   1 day 2.9 kg   
252 Sangeetha  19 
G3P1L1
A1 
V Preeclampsia LN 39 weeks   2 days 2.7 kg   
253 Kavitha 22 Primi V 
Severe 
Preeclampsia 
LSCS 37 weeks   3 weeks 2.3 kg   
254 Kanchana 27 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
29 weeks   3 weeks IUD IUD 
255 Abirami 20 Primi V Preeclampsia LSCS 35 weeks   3 weeks 1.6 kg Prematurity 
256 Pachaiyammal 23 G2P1L1 V Preeclampsia LN 38 weeks   1 day 2.2 kg IUGR 
257 Nalini 26 
G3P2L1
D1 
V 
Severe 
Preeclampsia 
LN 36 weeks PPH 10 days 2.4 kg Prematurity 
258 
Sabreena 
Begum 
21 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
26 weeks   2 weeks IUD IUD 
259 Yuvarani 29 Primi V Chronic HT LSCS 36 weeks     3.4 kg   
260 Ramya 20 Primi V Gestational HT LN 40 weeks   1 day 3.1 kg   
261 Venda 23 Primi V AP Eclampsia LSCS 38 weeks   10 days 2.4 kg   
262 Angujavalli 30 Primi V PP Eclampsia LN 35 weeks ARF 1 week 1.7 kg   
263 Valli 21 Primi V 
Severe 
Preeclampsia 
LN 38 weeks   1 week 2.2 kg IUGR 
264 Keerthana 19 Primi V Gestational HT LN 35 weeks   1 day 2.1 kg Prematurity 
265 Jamuna 20 Primi V Preeclampsia 
Assisted 
delivery 
40 weeks PPH 10 days 2.4 kg   
266 Kavitha 25 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
27 weeks   3 weeks IUD IUD 
267 Arpudhavalli 30 Primi V 
Severe 
Preeclampsia 
LSCS 34 weeks   1 week 1.5 kg Prematurity 
268 Devi 21 Primi V AP Eclampsia LN 39 weeks   3 weeks 2.4 kg IUGR 
269 Saranya 23 Primi V 
Severe 
Preeclampsia 
LN 37 weeks PPH 1 week 2.8 kg   
270 Sumithra 22 Primi V AP Eclampsia LSCS 32 weeks   10 days 1.4 kg Prematurity 
271 Kokila 30 G2P1L1 V Gestational HT 
Assisted 
delivery 
39 weeks   2 days 2.8 kg   
272 Valli 22 G2A1 V 
Severe 
Preeclampsia 
LSCS 37 weeks   10 days 3.5 kg   
273 Amudha 25 G2P1L1 V AP Eclampsia LSCS 36 weeks   3 weeks 2.8 kg   
274 Jayanthi  30 G3P2L2 V Preeclampsia LSCS 38 weeks   1 day 3.4 kg   
275 Bhuvaneswari 24 G2P1L1 V Gestational HT LSCS 39 weeks   1 day 2.7 kg   
276 Brindha 28 Primi V 
Severe 
Preeclampsia 
LSCS 27 weeks Abruptio placenta 3 weeks 1.4 kg 
Prematurity & 
Neonatal death 
277 Hemavathy 23 Primi V 
Severe 
Preeclampsia 
LN 36 weeks   10 days 2.2 kg Prematurity 
278 
Samundeeswar
i 
26 Primi V 
Severe 
Preeclampsia 
LSCS 30 weeks Abruptio placenta 3 weeks 1.7kg Prematurity 
279 Rameera 23 Primi V Preeclampsia LN 39 weeks   1 day 2.4 kg   
280 Meenatchi 26 Primi V Preeclampsia LSCS 40 weeks   2 days 2.3 kg   
281 Devi 28 
G3P1L1
A1 
V AP Eclampsia LN 31 weeks   1 week 1.5 kg Prematurity 
282 Parvatham 20 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   2 days 1.5 kg 
Prematurity & 
IUGR 
283 Karpagam 20 Primi V AP Eclampsia LSCS 38 weeks     1.7 kg   
  
 
 
284 Dhavamani 27 G2P1D1 V Gestational HT LN 37 weeks   1 day 2.3 kg Prematurity 
285 Srimathi 26 G2P1L1 V Preeclampsia LSCS 39 weeks   2 days 2.7 kg   
286 Meena 24 G2P1L1 V Gestational HT LSCS 38 weeks   2 days 2.7 kg   
287 Mahalakshmi 23 G2P1L1 V AP Eclampsia LSCS 38 weeks   1 week 2.2 kg IUGR 
288 Dhanalakshmi 23 G2P1L1 V Preeclampsia LN 38 weeks   1 day 2.1 kg IUGR 
289 Vanitha 24 Primi V 
Severe 
Preeclampsia 
LN 32 weeks   3 weeks 1.6 kg 
Prematurity & 
Neonatal death 
290 Vijayalakshmi 27 G2P1L1 V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
27 weeks Abruptio placenta   IUD IUD 
291 Amudha 23 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks   10 days 2.7 kg   
292 Shalini 25 Primi V AP Eclampsia LSCS 39 weeks   1 week 2.1 kg   
293 Dhanam 22 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   10 days 2.3 kg Prematurity 
294 
Mubeena 
Begum 
25 G2P1L1 V Gestational HT LN 38 weeks   1 day 2.7 kg   
295 Anuselvi 24 Primi V AP Eclampsia 
Spontaneous 
expulsion 
29 weeks   10 days IUD IUD 
296 Gayathri 26 Primi V 
Severe 
Preeclampsia 
LN 35 weeks   1 week 2.4 kg Prematurity 
297 Shobana 22 Primi V 
Severe 
Preeclampsia 
LSCS 39 weeks Abruptio placenta 2 weeks 2.8 kg   
298 Shankari 24 G2P1L1 V Preeclampsia LN 37 weeks   1 week 2.2 kg 
Prematurity & 
IUGR 
299 Sivagami 25 Primi V 
Severe 
Preeclampsia 
LN 35 weeks PPH 2 weeks 2.1 kg Prematurity 
300 Sameena 23 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks   1 week 2.8 kg   
301 Anitha 18 Primi V 
Severe 
Preeclampsia 
LSCS 33 weeks   1 week 1.5 kg Prematurity 
302 Kavitha 19 G2P1L1 V Gestational HT LSCS 38 weeks   2 days 2.6 kg   
303 Meena 24 G2P1L1 V PP Eclampsia LSCS 39 weeks   2 weeks 2.9 kg   
304 Latha 27 G3P2L2 V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
27 weeks   1 week IUD IUD 
305 Priya 23 Primi V 
Severe 
Preeclampsia 
LSCS 38 weeks Abruptio placenta 3 weeks 2.9 kg   
306 Hemavathy 20 G2A1 V 
Severe 
Preeclampsia 
LN 33 weeks   10 days 1.6 kg 
Birth asphyxia & 
Prematurity 
307 Vasantha 24 Primi V Preeclampsia 
Assisted 
delivery 
39 weeks   1 day 3.4 kg   
308 Kavya 27 G4P3L3 V AP Eclampsia LSCS 38 weeks CVA   1 week 2.3 kg   
309 Sasikala 19 G2A1 V 
Severe 
Preeclampsia 
LSCS 36 weeks     2.3 kg Prematurity 
310 Ramya 29 G3P2L2 V Preeclampsia LSCS 38 weeks   3 weeks 2.3 kg IUGR 
311 Meena  21 G2A1 V Gestational HT LN 39 weeks   2 days 2.6 kg   
312 Saranya 20 Primi V 
Severe 
Preeclampsia 
LN 36 weeks   10 days 2.1 kg Prematurity 
313 Vasanthi 18 G2P1L1 V Preeclampsia LSCS 39 weeks Abruptio placenta 2 days 2.8 kg   
314 Devi 19 Primi V AP Eclampsia LSCS 39 weeks   1 week 2.7 kg   
315 Kanchana 22 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 27 weeks PPH 3 weeks 1.3 kg Prematurity 
316 Kalaiarasi 28 G2P1L1 V Gestational HT LSCS 39 weeks   2 days 3.2 kg   
317 Mohanapriya 23 Primi V Preeclampsia LSCS 39 weeks   2 days 2.6 kg   
318 Surya 24 G2P1L1 V AP Eclampsia LSCS 38 weeks 
Abruptio placenta, 
HELLP, DIC, 
Pulmonary edema 
& Maternal Death 
  1.4 kg IUGR 
319 Lalitha 26 G3A2 V 
Severe 
Preeclampsia 
LN 35 weeks   1 week 1.6 kg 
Prematurity & 
IUGR 
320 Kalaivani 25 Primi V Preeclampsia LN 40 weeks   2 days 2.9 kg   
321 Saranya 21 G2P1L1 V Gestational HT LN 38 weeks   1 day 2.3 kg   
322 Meena 28 G3P2L2 V Preeclampsia LN 39 weeks   2 days 2.4 kg Birth asphyxia 
323 Lakshmi 17 Primi V AP Eclampsia LN 30 weeks ARF   1.7 kg Prematurity 
324 Sarala 22 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 35 weeks   1 week 1.8 kg 
Prematurity & 
IUGR 
325 Laila 18 Primi V Preeclampsia 
Assisted 
delivery 
40 weeks   1 week 2.9 kg   
  
 
 
326 Vanitha 20 G2A1 V 
Severe 
Preeclampsia 
LN 36 weeks PPH 10 days 2.8 kg Prematurity 
327 Suryakala 23 Primi V Gestational HT LN 39 weeks   1 day 2.7 kg   
328 Manopriya 24 G2P1L1 V Preeclampsia LSCS 40 weeks   2 days 2.6 kg   
329 Subashini 29 
G4P2L2
A1 
V AP Eclampsia LSCS 35 weeks   3 weeks 1.6 kg 
Prematurity & 
Neonatal death 
330 Laila 20 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks   2 weeks 1.9 kg Prematurity 
331 Revathy 19 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 37 weeks     2.2 kg Prematurity 
332 Gomathi 18 Primi V Preeclampsia LSCS 35 weeks   2 days 2.2 kg Prematurity 
333 Sheela  25 G2A1 V 
Severe 
Preeclampsia 
LSCS 37 weeks   3 weeks 2.3 kg   
334 Rani 22 G2P1L1 V Preeclampsia LSCS 39 weeks   1 day 2.2 kg   
335 Lakshmi 27 
G3P1L1
A1 
V 
Severe 
Preeclampsia 
LN 36 weeks   10 days 1.9 kg 
Prematurity & 
IUGR 
336 Kanaga 20 Primi V Gestational HT LSCS 39 weeks   2 days 3.3 kg   
337 Malini 23 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 32 weeks Abruptio placenta   1.8 kg Prematurity 
338 Manjula  18 Primi V Gestational HT LN 40 weeks   1 day 2.8 kg   
339 Samithra 26 G3P2L2 V Preeclampsia LN 39 weeks   1 day 3.4 kg   
340 Kanaga 19 G2P1L1 V Gestational HT LN 36 weeks   2 days 2.9 kg Prematurity 
341 Karpagam 17 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   1 week 2.1 kg Prematurity 
342 Thamarai 24 Primi V Preeclampsia 
Assisted 
delivery 
38 weeks   10 days 2.4 kg   
343 Vaidehi 18 Primi V AP Eclampsia Hysterotomy 33 weeks   2 weeks 1.5 kg Prematurity 
344 Muniyammal 20 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 39 weeks   2 days 2.8 kg   
345 Kasiyammal 25 G3P2L2 V Preeclampsia LSCS 38 weeks Abruptio placenta 2 days 2.3 kg   
346 Shobana 20 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   10 days 1.6 kg 
Birth asphyxia, 
Prematurity & 
Neonatal death 
347 Anisha 27 G4P3L3 V 
Severe 
Preeclampsia 
LSCS 33 weeks     1.5 kg Prematurity 
348 Devikala 25 Primi V Preeclampsia LSCS 39 weeks   1 day 1.8 kg IUGR 
349 Swathi 25 G2P1L1 V Gestational HT LSCS 40 weeks   2 days 3.5 kg   
350 Susila 22 Primi V Gestational HT LN 38 weeks   1 day 2.7 kg   
351 Meena  29 G4P3L3 V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
27 weeks Abruptio placenta 3 weeks IUD IUD 
352 Chitra 20 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks 
Abruptio placenta, 
HELLP & DIC 
  2.2 kg Prematurity 
353 Ambika 19 G2A1 V 
Severe 
Preeclampsia 
LN 38 weeks   10 days 2.7 kg   
354 Priya 30 Primi V PP Eclampsia LN 36 weeks   3 weeks 1.8 kg   
355 Srivathy 23 G3P2L2 V Preeclampsia LN 37 weeks   1 day 2.2 kg 
Prematurity & 
IUGR 
356 Sangeetha  23 Primi V Gestational HT LN 39 weeks   1 day 2.9 kg   
357 Dhanalakshmi 27 G3P2L2 V Gestational HT LN 38 weeks   1 day 2.6 kg   
358 Kokila 28 
G3P1L1
A1 
V 
Severe 
Preeclampsia 
LSCS 40 weeks   10 days 3.2 kg   
359 Poornima 19 Primi V 
Severe 
Preeclampsia 
LN 39 weeks PPH 1 week 2.8 kg   
360 Usha 18 Primi V AP Eclampsia LSCS 37 weeks Abruptio placenta 1 week 2.3 kg   
361 Ammu 20 G2P1L1 V 
Severe 
Preeclampsia 
LN 37 weeks   1 week 1.9 kg 
Prematurity & 
IUGR 
362 Sathyapriya 24 Primi V 
Severe 
Preeclampsia 
LSCS 38 weeks   3 weeks 2.3 kg   
363 Mercy 19 Primi V 
Severe 
Preeclampsia 
LN 37 weeks PPH 10 days 2.4 kg Prematurity 
364 Rooba 25 G3A2 V Gestational HT 
Assisted 
delivery 
38 weeks   2 days 3.6 kg   
365 Fathima 18 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
26 weeks Retinopathy   IUD IUD 
366 Yamuna 24 G2P1L1 V Preeclampsia LN 38 weeks   1 day 2.2 kg IUGR 
367 Sheela  19 G2P1L1 V AP Eclampsia LN 39 weeks CVA     2.7 kg Birth asphyxia 
368 Kanmani 27 
G4P1L1
A2 
V 
Severe 
Preeclampsia 
LN 39 weeks   1 day 2.8 kg   
  
 
 
369 Vijayalakshmi 22 Primi V Preeclampsia LSCS 39 weeks   1 week 2.2 kg   
370 Divyabharathi 20 G2A1 V 
Severe 
Preeclampsia 
LSCS 37 weeks Abruptio placenta   2.1 kg Stillbirth 
371 Bharathi 19 G2P1L1 V Preeclampsia LN 40 weeks   2 days 2.8 kg   
372 Nithya 18 Primi V AP Eclampsia LSCS 38 weeks   1 week 2.4 kg   
373 Deepa 21 G2P1L1 V Preeclampsia LSCS 40 weeks   2 days 2.9 kg   
374 Aarthi 28 G3P2L2 V 
Severe 
Preeclampsia 
LN 36 weeks   1 week 2.3 kg Prematurity 
375 Priya 18 Primi V Preeclampsia LN 39 weeks   2 days 2.6 kg   
376 Aruna 19 Primi V AP Eclampsia LSCS 39 weeks   1 week 2.9 kg   
377 Malathi 22 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 38 weeks PPH 10 days 2.6 kg   
378 Yamuna 23 G2P1L1 V Gestational HT LSCS 38 weeks   2 days 2.7 kg   
379 Rajakumari 24 Primi V Gestational HT LN 39 weeks   1 day 2.8 kg   
380 Thenmozhi 20 G2P1L1 V Preeclampsia 
Assisted 
delivery 
39 weeks   1 day 2.4 kg   
381 Rudra 22 G2P1L1 V AP Eclampsia LN 31 weeks   10 days 1.9 kg Prematurity 
382 Yashodha 23 G3A2 V 
Severe 
Preeclampsia 
LN 36 weeks PPH 10 days 2.4 kg Prematurity 
383 Gokulapriya 19 Primi V Preeclampsia LN 40 weeks   1 day 2.6 kg   
384 Kannagi 18 Primi V AP Eclampsia LSCS 37 weeks   10 days 1.6 kg IUGR 
385 Muniyammal 21 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 35 weeks   3 weeks 1.6 kg Prematurity 
386 Manjula  22 Primi V Gestational HT LN 38 weeks   2 days 2.8 kg   
387 Kalaivani 23 G3P2L2 V Gestational HT LSCS 39 weeks   1 day 3.2 kg   
388 Swathi 18 Primi V Gestational HT LN 39 weeks   1 day 2.9 kg   
389 Devi 20 Primi V AP Eclampsia LSCS 38 weeks   2 weeks 1.7 kg 
IUGR & Neonatal 
death 
390 Rani 25 G3P2L2 V Preeclampsia LSCS 40 weeks Abruptio placenta 2 days 2.8 kg   
391 Anitha 24 Primi V 
Severe 
Preeclampsia 
LSCS 37 weeks   10 days 2.2 kg Prematurity 
392 Ambikadevi 20 Primi V AP Eclampsia LN 39 weeks   10 days 2.4 kg   
393 RAni 18 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
25 weeks Abruptio placenta   IUD IUD 
394 Bagyalakshmi 25 Primi V Preeclampsia LSCS 40 weeks   1 day 2.9 kg   
395 Thulasi 19 Primi V PP Eclampsia LSCS 35 weeks     1.7 kg   
396 Tamilselvi 25 Primi V 
Severe 
Preeclampsia 
LN 39 weeks PPH 1 week 2.7 kg   
397 Paanjali 24 Primi V Gestational HT LSCS 40 weeks   2 days 3.5 kg   
398 Sathyavathy 23 Primi V Preeclampsia LSCS 40 weeks   2 days 2.4 kg   
399 Shankari 19 Primi V AP Eclampsia LSCS 36 weeks   10 days 1.9 kg   
400 Malliga 20 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
25 weeks   3 weeks IUD IUD 
401 Vanitha 21 Primi V Preeclampsia LSCS 40 weeks   2 days 3.6 kg   
402 Seetha 22 Primi V IP Eclampsia LN 38 weeks   10 days 2.4 kg Birth asphyxia 
403 Amsa 22 Primi V Gestational HT LSCS 39 weeks   2 days 3.4 kg   
404 Faridha 20 Primi V Preeclampsia LN 36 weeks   3 weeks 2.8 kg Prematurity 
405 Monisha 23 Primi V AP Eclampsia LSCS 39 weeks Abruptio placenta 1 week 2.7 kg   
406 Jagadheeswari 25 Primi V Preeclampsia LSCS 40 weeks   1 day 2.6 kg   
407 Kumari 25 G3P2L2 V PP Eclampsia LSCS 38 weeks   3 weeks 1.7 kg IUGR 
408 Sivagami 19 Primi V 
Severe 
Preeclampsia 
LN 36 weeks   1 week 2.3 kg Birth asphyxia 
409 Lakshmi 24 
G4P1L1
A2 
V Gestational HT LN 35 weeks   2 days 2.3 kg Prematurity 
410 Radha 18 Primi V Preeclampsia LSCS 39 weeks   10 days 2.3 kg   
411 Bhuvana 25 G2P1L1 V 
Severe 
Preeclampsia 
LSCS 36 weeks   10 days 2.7 kg Prematurity 
412 Ramani 19 Primi V AP Eclampsia LSCS 38 weeks   3 weeks IUD IUD 
413 Nathiya 21 Primi V Gestational HT LSCS 39 weeks   1 day 2.7 kg   
  
 
 
414 Sridevi 20 Primi V 
Severe 
Preeclampsia 
LN 39 weeks   1 week 2.8 kg   
415 Jhansi 22 Primi V 
Severe 
Preeclampsia 
LSCS 36 weeks   2 weeks 2.4 kg Prematurity 
416 Renuga 23 Primi V AP Eclampsia LN 37 weeks   10 days 1.8 kg IUGR 
417 Mullai 18 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks 
Abruptio placenta, 
HELLP & DIC 
  1.7 kg 
Prematurity, 
IUGR & Neonatal 
Death 
418 Ganga 24 Primi V Gestational HT LSCS 39 weeks   1 day 3.4 kg   
419 Rubini 25 G2P1L1 V Preeclampsia LN 39 weeks   1 day 2.1 kg IUGR 
420 Govindhammal 19 G2A1 V Preeclampsia LSCS 40 weeks   1 day 2.7 kg   
421 Sreedevi 21 Primi V 
Severe 
Preeclampsia 
LN 27 weeks Abruptio placenta   1.4 kg 
Prematurity & 
Neonatal death 
422 Indra 21 Primi V AP Eclampsia LSCS 30 weeks   10 days 1.5 kg 
Prematurity & 
Neonatal death 
423 Suganya 23 G2P1L1 V Gestational HT LN 39 weeks   2 days 2.8 kg   
424 Srimathi 18 Primi V 
Severe 
Preeclampsia 
LN 38 weeks   10 days 3.4 kg   
425 Noornisha 19 Primi V Gestational HT LSCS 39 weeks   1 day 2.9kg   
426 Parvathi 22 G2P1L1 V Preeclampsia LN 39 weeks   1 day 2.9 kg   
427 Kanniyammal 22 Primi V Gestational HT LN 38 weeks   1 day 3.2 kg   
428 Niranjana 20 Primi V AP Eclampsia LN 36 weeks   10 days 1.9 kg   
429 Archana 23 Primi V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
26 weeks PPH 2 weeks IUD IUD 
430 Ammu 19 Primi V Preeclampsia LSCS 40 weeks   2 days 3.2 kg   
431 Valli 25 G2P1L1 V PP Eclampsia LSCS 39 weeks     1.9 kg   
432 Kiruba 18 Primi V AP Eclampsia LSCS 36 weeks Abruptio placenta 1 week 1.6 kg 
Prematurity & 
Neonatal death 
433 Saritha 25 G2P1L1 V Gestational HT LN 38 weeks   1 day 2.8 kg   
434 Vanmathi 24 G2P1L1 V Gestational HT LSCS 39 weeks   1 day 3.4 kg   
435 Tamilmani 19 Primi V AP Eclampsia LN 35 weeks   10 days 1.6 kg Prematurity 
436 Kalpana 21 Primi V Preeclampsia LN 35 weeks   3 weeks 2.1 kg Prematurity 
437 Gauthami 19 Primi V Gestational HT LN 39 weeks   1 day  2.9 kg   
438 Valli 18 G2A1 V Preeclampsia LSCS 40 weeks Abruptio placenta 10 days 2.6 kg   
439 Padmini 22 G2A1 V 
Severe 
Preeclampsia 
LSCS 36 weeks   1 week 2.7 kg Prematurity 
440 Vembu 23 Primi V AP Eclampsia LSCS 37 weeks CVA   3 weeks 1.9 kg   
441 Madhavi 20 Primi V Preeclampsia LN 40 weeks   1 day 2.7 kg   
442 Maheswari 22 G2P1L1 V Preeclampsia LSCS 39 weeks   1 day 2.3 kg   
443 Gowri 18 Primi V Gestational HT 
Assisted 
delivery 
39 weeks   2 days 2.4 kg   
444 Rasathi 23 G2A1 V Gestational HT LSCS 38 weeks   2 days 2.6 kg   
445 Ammulu 23 Primi V 
Severe 
Preeclampsia 
LN 38 weeks PPH 3 weeks 2.8 kg   
446 Preetha 19 Primi V 
Severe 
Preeclampsia 
LSCS 35 weeks   10 days 1.8 kg 
Prematurity & 
IUGR 
447 Vidhya 24 G2P1L1 V 
Severe 
Preeclampsia 
Spontaneous 
expulsion 
25 weeks     IUD IUD 
448 Arivazhagi 18 Primi V AP Eclampsia LN 28 weeks   1 week 0.8 kg 
Prematurity & 
Neonatal death 
449 Valarmathi 25 G2P1L1 V Preeclampsia LN 39 weeks   1 week 2.3 kg   
450 Deepthi 19 Primi V Gestational HT LSCS 39 weeks   1 day  3.2 kg   
 
